Loading... Please wait.

• Mutation
• Tumor-specific
• Differentiation
• Overexpressed
• Potential

Gene/Protein ⓘ	Normal/Tumor ⓘ	HLA ⓘ	HLA% ⓘ	Peptide Sequence ⓘ	Position ⓘ	Lymphocyte Stimulation ⓘ	Reference ⓘ	Full Reference	Note	Note ⓘ
CDK12	melanoma	A11	13	CILGKLFTK	924-932	autologous tumor cells	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. doi: 10.1038/nm.3161. (PMID: 23644516)
Cdc27	melanoma	DR4	24	FSWAMDLDPKGA	760-771	autologous tumor cells	Wang, 1999	Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999 May 21, 284(5418):1351-4. (PMID: 10334988)	The mutation is not located in the region encoding the peptide
alpha-actinin-4	lung carcinoma	A2	44	FIASNGVKLV	118-127	autologous tumor cells	Echchakir, 2001	Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S, Coulie PG. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 2001 May 15, 61(10):4078-83. (PMID: 11358829)
CASP-8	head and neck squamous cell carcinoma	B35	20	FPSDSWCYF	476-484	autologous tumor cells	Mandruzzato, 1997	Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997 Aug 29, 186(5):785-93. (PMID: 9271594)
CDKN2A	melanoma	A11	13	AVCPWTWLR	125-133 (p14ARF-ORF3)	autologous tumor cells	Huang, 2004	Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004 May 15, 172(10):6057-64. (PMID: 15128789)
COA-1	colorectal carcinoma	DR13	19	TLYQDDTLTLQAAG	447-460	autologous tumor cells	Maccalli, 2003	Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res. 2003 Oct 15, 63(20):6735-43. (PMID: 14583468)	The mutation is not located in the region encoding the peptide
CLPP	melanoma	A2	44	ILDKVLVHL	240-248	autologous tumor cells	Corbière, 2011	Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011 Feb 15, 71(4):1253-62. (PMID: 21216894)
COA-1	colorectal carcinoma	DR4	24	TLYQDDTLTLQAAG	447-460	autologous tumor cells	Maccalli, 2003	Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res. 2003 Oct 15, 63(20):6735-43. (PMID: 14583468)	The mutation is not located in the region encoding the peptide
CSNK1A1	melanoma	A2	44	GLFGDIYLA	26-34	autologous tumor cells	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516)
EFTUD2	melanoma	A3	22	KILDAVVAQK	668-677	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
FN1	melanoma	DR2	25	MIFEKHGFRRTTPP	2050-2063	autologous tumor cells	Wang, 2002	Wang HY, Zhou J, Zhu K, Riker AI, Marincola FM, Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med. 2002 Jun 3, 195(11):1397-406. (PMID: 12045238)
Elongation factor 2	lung squamous CC	A68	8	ETVSEQSNV	581-589	autologous tumor cells	Hogan, 1998	Hogan KT, Eisinger DP, Cupp SB 3rd, Lekstrom KJ, Deacon DD, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr, Ross MM. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 1998 Nov 15, 58(22):5144-50. (PMID: 9823325)
GAS7	melanoma	A2	44	SLADEAEVYL	141-150	autologous tumor cells	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516)
PPP1R3B	melanoma	A1	26	YTDFHCQYV	172-180	autologous tumor	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516)
CDK4	melanoma	A2	44	ACDPHSGHFV	23-32	autologous tumor cells	Wolfel, 1995	Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995 Sep 1, 269(5228):1281-4. (PMID: 7652577)
ARTC1	melanoma	DR1	18	YSVYFNLPADTIYTN		autologous tumor cells	Wang, 2005	Wang HY, Peng G, Guo Z, Shevach EM, Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005 Mar 1, 174(5):2661-70. (PMID: 15728473)	The mutation creates a start codon (ATG) that opens an alternative ORF encoding the antigenic peptide. This peptide is recognized by regulatory T cells (Tregs)
GPNMB	melanoma	A3	22	TLDWLLQTPK	179-188	autologous tumor cells	Lennerz, 2005	Lennerz V1, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
beta-catenin	melanoma	A24	20	SYLDSGIHF	29-37	autologous tumor cells	Robbins, 1996	Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996 Mar 1, 183(3):1185-92. (PMID: 8642260)
LDLR-fucosyltransferaseAS fusion protein	melanoma	DR1	18	WRRAPAPGA	315-323	autologous tumor cells	Wang, 1999	Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med. 1999 May 17, 189(10):1659-68. (PMID: 10330445)
HLA-A2	renal cell carcinoma					autologous tumor cells	Brändle, 1996	Brändle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med. 1996 Jun 1, 183(6):2501-8. (PMID: 8676070)	The mutation affects the HLA itself
HAUS3	melanoma	A2	44	ILNAMIAKI	154-162	autologous tumor cells	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516)
hsp70-2	renal cell carcinoma	A2	44	SLFEGIDIYT	286-295	autologous tumor cells	Gaudin, 1999	Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol. 1999 Feb 1, 162(3):1730-8.
MATN	melanoma	A11	13	KTLTSVFQK	226-234	autologous tumor cells	Robbins, 2013	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013 Jun, 19(6):747-52. (PMID: 23644516)
ME1	non-small cell lung carcinoma	A2	44	FLDEFMEGV	224-232	autologous tumor cells	Karanikas, 2001	Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res. 2001 May 1, 61(9):3718-24. (PMID: 11325844)
KIAAO205	bladder tumor	B44	21	AEPINIQTW	262-270	autologous tumor cells	Guéguen, 1998	Guéguen M, Patard JJ, Gaugler B, Brasseur F, Renauld JC, Van Cangh PJ, Boon T, Van den Eynde BJ. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol. 1998 Jun 15, 160(12):6188-94. (PMID: 9637538)
MUM-1	melanoma	B44	21	EEKLIVVLF	30-38	autologous tumor cells	Coulie, 1995	Coulie PG, Lehmann F, Lethé B, Herman J, Lurquin C, Andrawiss M, Boon T. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995 Aug 15, 92(17):7976-80. (PMID: 7644523)
MUM-2	melanoma	B44	21	SELFRSGLDSY	123-133	autologous tumor cells	Chiari, 1999	Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999 Nov 15, 59(22):5785-92. (PMID: 10582700)
MUM-2	melanoma	Cw6	18	FRSGLDSYV	126-134	autologous tumor cells	Chiari, 1999	Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999 Nov 15, 59(22):5785-92. (PMID: 10582700)
MUM-3	melanoma	A68	8	EAFIQPITR	322-330	autologous tumor cells	Baurain, 2000	Baurain JF, Colau D, van Baren N, Landry C, Martelange V, Vikkula M, Boon T, Coulie PG. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol. 2000 Jun 1, 164(11):6057-66. (PMID: 10820291)
LDLR-fucosyltransferaseAS fusion protein	melanoma	DR1	18	PVTWRRAPA	312-320	autologous tumor cells	Wang, 1999	Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med. 1999 May 17, 189(10):1659-68. (PMID: 10330445)
neo-PAP	melanoma	DR7	25	RVIKNSIRLTL	724-734	autologous tumor cells	Topalian, 2002	Topalian SL, Gonzales MI, Ward Y, Wang X, Wang RF. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 2002 Oct 1, 62(19):5505-9. (PMID: 12359760)	The mutation is not located in the region encoding the peptide
MART2	melanoma	A1	26	FLEGNEVGKTY	446-455	autologous tumor cells	Kawakami, 2001	Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis J, Fitzgerald E, Rosenberg S. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001 Feb 15, 166(4):2871-7. (PMID: 11160356)
NFYC	lung squamous cell carcinoma	B52	5	QQITKTEV	275-282	autologous tumor cells	Takenoyama, 2006	Takenoyama M, Baurain JF, Yasuda M, So T, Sugaya M, Hanagiri T, Sugio K, Yasumoto K, Boon T, Coulie PG. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer. 2006 Apr 15, 118(8):1992-7. (PMID: 16287085)
HLA-A11	melanoma					autologous tumor cells	Huang, 2004	Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol. 2004 May 15, 172(10):6057-64. (PMID: 15128789)	The mutation affects the HLA itself
OS-9	melanoma	B44	21	KELEGILLL	438-446	autologous tumor cells	Vigneron, 2002	Vigneron N, Ooms A, Morel S, Degiovanni G, Van den Eynde B. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. 2002 January.
PTPRK	melanoma	DR10	3	PYYFAAELPPRNLPEP	667-682	autologous tumor cells	Novellino, 2003	Novellino L, Renkvist N, Rini F, Mazzocchi A, Rivoltini L, Greco A, Deho P, Squarcina P, Robbins PF, Parmiani G, Castelli C. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol. 2003 Jun 15, 170(12):6363-70. (PMID: 12794170)
HSDL1	ovarian cancer	Cw14	4	CYMEAVAL	20-27	autologous tumor cells	Wick, 2013	Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, Nelson BH. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res. 2014 Mar 1, 20(5):1125-34. (PMID: 24323902)
RBAF600	melanoma	B7	17	RPHVPESAF	329-337	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
N-ras	melanoma	A1	26	ILDTAGREEY	55-64	autologous tumor cells	Linard, 2002	Linard B, Bézieau S, Benlalam H, Labarrière N, Guilloux Y, Diez E, Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol. 2002 May 1, 168(9):4802-8. (PMID: 11971032)
SIRT2	melanoma	A3	22	KIFSEVTLK	192-200	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
SNRPD1	melanoma	B38	5	SHETVIIEL	10-19	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
Triosephosphate isomerase	melanoma	DR1	18	GELIGILNAAKVPAD	23-37	autologous tumor cells	Pieper, 1999	Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med. 1999 Mar 1, 189(5):757-66. (PMID: 10049939)
BCR-ABL fusion protein (b3a2)	chronic myeloid leukemia	B8	14	GFKQSSKAL	922-930	peptide	Yotnda, 1998	Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998 May 15, 101(10):2290-6. (PMID: 9593785)
Myosin class I	melanoma	A3	22	KINKNPKYK	911-919	expansion of TIL with IL-2	Zorn, 1999	Zorn E, Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol. 1999 Feb, 29(2):592-601. (PMID: 10064075)
BCR-ABL fusion protein (b3a2)	chronic myeloid leukemia	DR4	24	ATGFKQSSKALQRPVAS	920-936	peptide	Bosch, 1996	Bosch GJ, Joosten AM, Kessler JH, Melief CJ, Leeksma OC. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood. 1996 Nov 1, 88(9):3522-7. (PMID: 8896419)
BCR-ABL fusion protein (b3a2)	chronic myeloid leukemia	A2	44	SSKALQRPV	926-934	peptide	Yotnda, 1998	Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest. 1998 May 15, 101(10):2290-6. (PMID: 9593785)
BCR-ABL fusion protein (b3a2)	chronic myeloid leukemia	DR9	3	ATGFKQSSKALQRPVAS	920-936	peptide	Makita, 2002	Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002 Dec, 16(12):2400-7. (PMID: 1245474)
B-RAF	melanoma	DR4	24	EDLTVKIGDFGLATEKSRWSGSHQFEQLS	586-614	peptide	Sharkey, 2004	Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 2004 Mar 1, 64(5):1595-9. (PMID: 14996715)
dek-can fusion protein	myeloid leukemia	DR53	49	TMKQICKKEIRRLHQY	342-357	peptide	Makita, 2002	Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujita S, Tanimoto M, Harada M, Yasukawa M. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002 Dec, 16(12):2400-7. (PMID: 12454745)
ETV6-AML1 fusion protein	acute lymphoblastic leukemia	A2	44	RIAECILGM	334-342	peptide	Yotnda, 1998	Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F, Vilmer E, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest. 1998 Jul 15, 102(2):455-62. (PMID: 9664088)
ETV6-AML1 fusion protein	acute lymphoblastic leukemia	DP5	3	IGRIAECILGMNPSR	332-346	peptide	Yun, 1999	Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens. 1999 Aug, 54(2):153-61. (PMID: 10488742)
CASP-5	colorectal, gastric, and endometrial carcinoma	A2	44	FLIIWQNTM	67-75	peptide	Schwitalle, 2004	Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. 2004 January	Frameshift product
ETV6-AML1 fusion protein	acute lymphoblastic leukemia	DP17	1	IGRIAECILGMNPSR	332-346	peptide	Yun, 1999	Yun C, Senju S, Fujita H, Tsuji Y, Irie A, Matsushita S, Nishimura Y. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens. 1999 Aug, 54(2):153-61. (PMID: 10488742)
FLT3-ITD	acute myelogenous leukemia	A1	26	YVDFREYEYY	591-600	peptide	Graf, 2007	Graf C, Heidel F, Tenzer S, Radsak MP, Solem FK, Britten CM, Huber C, Fischer T, Wölfel T. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2007 Apr 1, 109(7):2985-8. (PMID: 17119119)
OGT	colorectal carcinoma	A2	44	SLYKFSPFPL	28-37	peptide	Ripberger, 2003	Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol. 2003 Sep, 23(5):415-23. (PMID: 14601650)	Frameshift product
FNDC3B	chronic lymphocytic leukemia	A2	44	VVMSWAPPV	292-300	peptide	Rajasagi, 2004	Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, Hacohen N, Wu CJ. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17, 124(3):453-62. (PMID: 24891321)
p53	head and neck squamous cell carcinoma	A2	44	VVPCEPPEV	217-225	peptide	Ito, 2007	Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris RL, DeLeo AB. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer. 2007 Jun 15, 120(12):2618-24. (PMID: 17294448)
pml-RARalpha fusion protein	promyelocytic leukemia	DR11	25	NSNHVASGAGEAAIETQSSSSEEIV		peptide	Gambacorti, 1993	Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood. 1993 Mar 1, 81(5):1369-75. (PMID: 8095167)
PRDX5	melanoma	A2	44	LLLDDLLVSI	163-172	peptide	Sensi, 2005	Sensi M, Nicolini G, Zanon M, Colombo C, Molla A, Bersani I, Lupetti R, Parmiani G, Anichini A. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res. 2005 Jan 15, 65(2):632-40. (PMID: 15695408)
K-ras	pancreatic adenocarcinoma	B35	20	VVVGAVGVG	7-15	peptide	Gjertsen, 1997	Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 1997 Sep 4, 72(5):784-90. (PMID: 9311595)
SYT-SSX1 or -SSX2 fusion protein	sarcoma	B7	17	QRPYGYDQIM	402-410 (SYT)	peptide	Worley, 2001	Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15, 61(18):6868-75. (PMID: 11559563)
TGF-betaRII	colorectal carcinoma	A2	44	RLSSCVPVA	131-139	peptide	Linnebacher, 2001	Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer. 2001 Jul 1, 93(1):6-11. (PMID: 11391614)	Frameshift product
K-ras	metastatic colorectal cancer	Cw8	7	GADGVGKSA	10-18	autologous tumor cells	Tran, 2016	Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23): 2255-2262. (PMID: 27959684)
K-ras	metastatic colorectal cancer	Cw8	7	GADGVGKSAL	10-19	autologous tumor cells	Tran, 2016	Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016; 375(23): 2255-2262. (PMID: 27959684)
TP53		A2	44	VVPCEPPEV	217-225	expansion of TIL	Malekzadeh, 2019	Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, Deniger DC. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest. 2019 Mar 1, 129(3):1109-1114. (PMID: 30714987)
AP2S1	Colorectal cancer	A24	20	AYLEAIHKF	79-87	peptide	Shinkawa, 2021	Shinkawa T, Tokita S, Nakatsugawa M, Kikuchi Y, Kanaseki T, Torigoe T. Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions. Oncoimmunology. 2021 10(1):1870062. (PMID: 33537174)

Gene/Protein ⓘ	Normal/Tumor ⓘ	HLA ⓘ	HLA% ⓘ	Peptide Sequence	Position ⓘ	Lymphocyte Stimulation ⓘ	Reference ⓘ	Full Reference	Note	Note ⓘ
D393-CD20n		DR4	24	KPLFRRMSSLELVIA	28-42	peptide	Vauchy, 2015	Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer. 2015 Jul 1, 137(1):116-26. (PMID: 25449106)
KK-LC-1		B15	13	RQKRILVNL	76-84	autologous tumor cells	Fukuyama, 2006	Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, Sugaya M, So T, Sugio K, Yasumoto K. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006 May 1, 66(9):4922-8. (PMID: 16651449)
HERV-K-MEL		A2	44	MLAVISCAV	1-9	autologous tumor cells	Schiavetti, 2002	Schiavetti F1, Thonnard J, Colau D, Boon T, Coulie PG. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 2002 Oct 1, 62(19):5510-6. (PMID: 12359761)
BAGE-1		Cw16	7	AARAVFLAL	2-10	autologous tumor cells	Boel, 1995	Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995 Feb, 2(2):167-75. (PMID: 7895173)
GAGE-1,2,8		Cw6	18	YRPRPRRY	9-16	autologous tumor cells	Van den Eynde, 1995	Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995 Sep 1, 182(3):689-98.
GAGE-3,4,5,6,7		A29	6	YYWPRPRRY	10-18	autologous tumor cells	De Backer, 1999	De Backer O1, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 1999 Jul 1, 59(13):3157-65. (PMID: 10397259)
MAGE-A9		A2	44	ALSVMGVYV	223-231	peptide	Oehlrich, 2005	Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605)
NA88-A		B13	6	QGQHFLQKV		tumor-infiltrating lymphocytes	Moreau-Aubry, 2000	Moreau-Aubry A, Le Guiner S, Labarrière N, Gesnel MC, Jotereau F, Breathnach R. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med. 2000 May 1, 191(9):1617-24. (PMID: 10790436)
SSX-4		DP10	2	INKTSGPKRGKHAWTHRLRE	151-170	peptide	Ayyoub, 2005	Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740)
SSX-4		DR3	21	YFSKKEWEKMKSSEKIVYVY	31-50	peptide	Ayyoub, 2005	Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740)
SSX-4		DR8	4	KHAWTHRLRERKQLVVYEEI	161-180	peptide	Valmori, 2006	Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478)
SSX-4		DR8	4	MKLNYEVMTKLGFKVTLPPF	51-70	peptide	Valmori, 2006	Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478)
SSX-4		DR15	20	KSSEKIVYVYMKLNYEVMTK	41-60	peptide	Ayyoub, 2005	Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740)
TAG-1		A2	44	SLGWLFLLL	78-86	peptide	Adair, 2008	Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007)
SSX-4		DR11	25	LGFKVTLPPFMRSKRAADFH	61-80	peptide	Ayyoub, 2005	Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D. CD4+ T cell responses to SSX-4 in melanoma patients. J Immunol. 2005 Apr 15, 174(8):5092-9. (PMID: 15814740)
TRAG-3		DR1	18	CEFHACWPAFTVLGE	34-48	peptide	Janjic, 2006	Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034)
TAG-1		B8	14	LSRLSNRLL	42-50	peptide	Adair, 2008	Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007)
TAG-2		B8	14	LSRLSNRLL	42-50	peptide	Adair, 2008	Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J Immunother. 2008 Jan, 31(1):7-17. (PMID: 18157007)
SSX-4		DR52	41	KHAWTHRLRERKQLVVYEEI	161-180	peptide	Valmori, 2006	Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ, Odunsi K. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 2006 Jan 15, 12(2):398-404. (PMID: 16428478)
TRAG-3		DR4	24	CEFHACWPAFTVLGE	34-48	peptide	Janjic, 2006	Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034)
TRAG-3		DR7	25	CEFHACWPAFTVLGE	34-48	peptide	Janjic, 2006	Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15, 177(4):2717-27. (PMID: 16888034)
XAGE-1b/GAGED2a		A2	44	RQKKIRIQL	21-29	peptide	Ohue, 2012	Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer. 2012 Sep 1, 131(5):E649-58. (PMID: 22109656)
XAGE-1b/GAGED2a		DR4	24	HLGSRQKKIRIQLRSQ	17-32	peptide	Ohue, 2012	Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer. 2012 Sep 1, 131(5):E649-58. (PMID: 22109656)
XAGE-1b/GAGED2a		DR9	3	CATWKVICKSCISQTPG	33-49	autologous tumor cells	Shimono, 2007	Shimono M, Uenaka A, Noguchi Y, Sato S, Okumura H, Nakagawa K, Kiura K, Tanimoto M, Nakayama E. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. Int J Oncol. 2007 Apr, 30(4):835-40. (PMID: 17332921)
HERV-E		A11	13	ATFLGSLTWK		autologous tumor cells	Takahashi, 2008	Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K-i, Mena O, Kurlander R, Abdul T, Srinivasan R, Lundqvist A, Malinzak E, Geller N, Lerman MI, Childs RW. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008 Mar 3, 118(3):1099–1109. (PMID: 18292810)
Cyclin-A1		A2	44	SLIAAAAFCLA	341-351	peptide	Ochsenreither, 2012	Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012 Jun 7, 119(23):5492-501. (PMID: 22529286)
Cyclin-A1		A2	44	FLDRFLSCM	227-235	peptide	Ochsenreither, 2012	Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood. 2012 Jun 7, 119(23):5492-501. (PMID: 22529286)
KM-HN-1		A24	20	NYNNFYRFL	196-204	peptide	Monji, 2004	Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989)
KM-HN-1		A24	20	EYSKECLKEF	499-508	peptide	Monji, 2004	Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989)
LAGE-1		A2	44	MLMAQEALAFL	ORF2	autologous tumor cells	Aarnoudse, 1999	Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963)
KM-HN-1		A24	20	EYLSLSDKI	770-778	peptide	Monji, 2004	Monji M, Nakatsura T, Senju S, Yoshitake Y, Sawatsubashi M, Shinohara M, Kageshita T, Ono T, Inokuchi A, Nishimura Y. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Clin Cancer Res. 2004 Sep 15, 10(18 Pt 1):6047-57. (PMID: 15447989)
LAGE-1		A2	44	MLMAQEALAFL	(1-11)	autologous tumor cells	Aarnoudse, 1999	Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963)
LAGE-1		A2	44	SLLMWITQC	157-165	peptide	Rimoldi, 2000	Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol. 2000 Dec 15, 165(12):7253-61. (PMID: 11120859)
LAGE-1		A31	5	LAAQERRVPR	ORF2	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882)
LAGE-1		A31	5	LAAQERRVPR	(18-27)	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882)
LAGE-1		B7	17	APRGVRMAV	ORF2	adenovirus-APC	Slager, 2004	Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004 Mar, 11(3):227-36. (PMID: 14726960)
LAGE-1		A68	8	ELVRRILSR	103-111	adenovirus-dendritic cells	Sun, 2006	Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother. 2006 Jun, 55(6):644-52. (PMID: 16187088)
LAGE-1		B7	17	APRGVRMAV	( 46-54)	adenovirus-APC	Slager, 2004	Slager EH, van der Minne CE, Goudsmit J, van Oers JM, Kostense S, Havenga MJ, Osanto S, Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004 Mar, 11(3):227-36. (PMID: 14726960)
LAGE-1		DR3	21	QGAMLAAQERRVPRAAEVPR	ORF2	protein	Slager, 2004	Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093)
LAGE-1		DR3	21	QGAMLAAQERRVPRAAEVPR	(14-33)	protein	Slager, 2004	Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093)
LAGE-1		DR12	5	CLSRRPWKRSWSAGSCPGMPHL	(81-102)	peptide	Slager, 2003	Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712)
LAGE-1		DR13	19	ILSRDAAPLPRPG	108-120	autologous tumor cells	Wang, 2004	Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004 Jan, 20(1):107-18. (PMID: 14738769)
LAGE-1		DR11	25	CLSRRPWKRSWSAGSCPGMPHL	ORF2	peptide	Slager, 2003	Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712)
LAGE-1		DR15	20	AGATGGRGPRGAGA	37-50	protein	Hasegawa, 2006	Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006 Mar 15, 12(6):1921-7. (PMID: 16551878)
LAGE-1		DR11	25	CLSRRPWKRSWSAGSCPGMPHL	(81-102)	peptide	Slager, 2003	Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712)
LY6K		A24	20	RYCNLEGPPI	119-128	peptide	Suda, 2007	Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov, 98(11), 1803-8. (PMID: 17784873)
LY6K		DR15	20	KCCKIRYCNLEGPPINSSVF	114-133	peptide	Tomita, 2014	Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Oncoimmunology. 2014 Mar 27, e28100. (PMID: 25340007)
LY6K		DP5	3	KWTEPYCVIAAVKIFPRFFMVAKQ	61-84	peptide	Tomita, 2014	Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A, Hamada A, Jono H, Yoshida K, Tsunoda T, Daigo Y, Kohrogi H, Yoshitake Y, Nakamura Y, Shinohara M, Nishimura Y. Identification of immunogenic LY6K long peptide encompassing both CD4+ and CD8+ T-cell epitopes and eliciting CD4+ T-cell immunity in patients with malignant disease. Oncoimmunology. 2014 Mar 27, e28100. (PMID: 25340007)
MAGE-A1		A1	26	EADPTGHSY	161-169	autologous tumor cells	Traversari, 1992	Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1, 176(5):1453-7. (PMID: 1402688)
MAGE-A1		A2	44	KVLEYVIKV	278-286	peptide	Pascolo, 2001	Pascolo S, Schirle M, Gückel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG, Stevanovic S. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001 May 15, 61(10):4072-7. (PMID: 11358828)
MAGE-A1		A3	22	SLFRAVITK	96-104	poxvirus-dendritic cells	Chaux, 1999		ALVAC recombinant proxvirus carrying the entire gene were used to infect dentritic cells.
MAGE-A1		A2	44	KVLEYVIKV	278-286	peptide	Ottaviani, 2005	Ottaviani S, Zhang Y, Boon T, van der Bruggen P. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother. 2005 Dec, 54(12):1214-20. (PMID: 16025263)
LAGE-1		DR4	24	AADHRQLQLSISSCLQQL	139-156	protein	Jäger, 2000	Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854)
LAGE-1		DP4	75	SLLMWITQCFLPVF	157-170	peptide	Zeng, 2001	Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001 Mar 27, 98(7):3964-9. (PMID: 11259659)
LAGE-1		DR12	5	CLSRRPWKRSWSAGSCPGMPHL	ORF2	peptide	Slager, 2003	Slager EH, Borghi M, van der Minne CE, Aarnoudse CA, Havenga MJ, Schrier PI, Osanto S, Griffioen M. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J Immunol. 2003 Feb 1, 170(3):1490-7. (PMID: 12538712)
MAGE-A1		A68	8	EVYDGREHSA	222-231	poxvirus-dendritic cells	Chaux, 1999	Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36.
MAGE-A1		B7	17	RVRFFFPSL	289-298	poxvirus-dendritic cells	Luiten, 2000	Luiten R, van der Bruggen P. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. Tissue Antigens. 2000 Feb, 55(2):149-52. (PMID: 10746786)
MAGE-A1		B35	20	EADPTGHSY	161-169	poxvirus-dendritic cells	Luiten, 2000	Luiten RM, Demotte N, Tine J, van der Bruggen P. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000 Jul, 56(1):77-81. (PMID: 10958359)
MAGE-A1		B37	3	REPVTKAEML	120-129	autologous tumor cells	Tanzarella, 1999	Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990)
MAGE-A1		B44	21	KEADPTGHSY	160-169	poxvirus-dendritic cells	Stroobant, 2012	Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N. Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. Eur J Immunol. 2012 Jun, 42(6):1417-28. (PMID: 22678898)
MAGE-A1		B53	2	DPARYEFLW	258-266	poxvirus-dendritic cells	Chaux, 1999	Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041)
MAGE-A1		B57	8	ITKKVADLVGF	102-112	ALVAC-dendritic cells	Corbière, 2004	Corbière V, Nicolay H, Russo V, Stroobant V, Brichard V, Boon T, van der Bruggen P. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors. Tissue Antigens. 2004 May, 63(5):453-7. (PMID: 15104676)
MAGE-A1		Cw2	10	SAFPTTINF	62-70	poxvirus-dendritic cells	Chaux, 1999	Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041)
MAGE-A1		Cw3	17	SAYGEPRKL	230-238	poxvirus-dendritic cells	Chaux, 1999	Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041)
MAGE-A1		Cw7	41	RVRFFFPSL	289-298	peptide	Goodyear, 2011	Goodyear OC1, Pearce H, Pratt G, Moss P. Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer Immunol Immunother. 2011 Dec, 60(12):1751-61. (PMID: 21785964)
MAGE-A1		DP4	75	TSCILESLFRAVITK	90-104	peptide	Wang, 2007	Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823)
MAGE-A1		Cw16	7	SAYGEPRKL	230-238	autologous tumor cells	van der Bruggen, 1994	van der Bruggen P1, Szikora JP, Boël P, Wildmann C, Somville M, Sensi M, Boon T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur J Immunol. 1994 Sep, 24(9):2134-40. (PMID: 7522162)
MAGE-A1		DR13	19	FLLLKYRAREPVTKAE	112-127	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-A1		DP4	75	PRALAETSYVKVLEY	268-282	peptide	Wang, 2007	Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823)
MAGE-A2		A2	44	YLQLVFGIEV	157-166	peptide	Kawashima, 1998	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234)
MAGE-A1		DR15	20	EYVIKVSARVRF	281-292	protein	Chaux, 2001	Chaux P, Lethé B, Van Snick J, Corthals J, Schultz ES, Cambiaso CL, Boon T, van der Bruggen P. A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells. Eur J Immunol. 2001 Jun, 31(6):1910-6. (PMID: 11433388)
MAGE-A2		A24	20	EYLQLVFGI	156-164	peptide	Tahara, 1999	Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 1999 Aug, 5(8):2236-41. (PMID: 10473111)
GnTV		A2	44	VLPDVFIRC(V)	intron	autologous tumor cells	Guilloux, 1996	Guilloux Y1, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethé B, Jotereau F, Boon T. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 1996 Mar 1, 183(3):1173-83. (PMID: 8642259)	Aberrant transcript of N acetyl glucosaminyl transferase V (GnTV) that is found only in melanomas.
MAGE-A2		Cw7	41	EGDCAPEEK	212-220	lentivirus-dendritic cells	Breckpot, 2004	Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691)
MAGE-A3		A2	44	KVAELVHFL	112-120	peptide	Kawashima, 1998	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234)
MAGE-A3		A1	26	EVDPIGHLY	168-176	autologous tumor cells	Gaugler, 1994	Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1, 179(3):921-30. (PMID: 8113684)
MAGE-A3		A24	20	TFPDLESEF	97-105	peptide	Oiso, 1999	Oiso M, Eura M, Katsura F, Takiguchi M, Sobao Y, Masuyama K, Nakashima M, Itoh K, Ishikawa T. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes. Int J Cancer. 1999 May 5, 81(3):387-94. (PMID: 10209953)
MAGE-A3		B18	6	MEVDPIGHLY	167-176	adeno-dendritic cells	Bilsborough, 2002	Bilsborough J, Panichelli C, Duffour MT, Warnier G, Lurquin C, Schultz ES, Thielemans K, Corthals J, Boon T, van der Bruggen P. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18. Tissue Antigens. 2002 Jul, 60(1):16-24. (PMID: 12366779)
MAGE-A3		B35	20	EVDPIGHLY	168-176	poxvirus-dendritic cells	Schultz, 2001	Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens. 2001 Feb, 57(2):103-9. (PMID: 11260504)
MAGE-A3		B37	3	REPVTKAEML	127-136	autologous tumor cells	Tanzarella, 1999	Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990)
MAGE-A3		B44	21	MEVDPIGHLY	167-176	peptide	Herman, 1996	Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG. A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics. 1996, 43(6):377-83. (PMID: 8606058)
MAGE-A3		B40	6	AELVHFLLL	114-122	adeno-dendritic cells	Schultz, 2002	Schultz ES, Chapiro J, Lurquin C, Claverol S, Burlet-Schiltz O, Warnier G, Russo V, Morel S, Lévy F, Boon T, Van den Eynde BJ, van der Bruggen P. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002 Feb 18, 195(4):391-9. (PMID: 11854353)	The processing of this peptide requires immunoproteasome.
MAGE-A3		B52	5	WQYFFPVIF	143-151	retrovirus-dendritic cells	Russo, 2000	Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, Bordignon C, Traversari C. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A. 2000 Feb 29, 97(5):2185-90. (PMID: 10681453)	Retrovirus carrying the entire gene were used to infect dentritic celles.
MAGE-A3		DP4	75	KKLLTQHFVQENYLEY	243-258	protein	Schultz, 2000	Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res. 2000 Nov 15, 60(22):6272-5. (PMID: 11103782)
MAGE-A3		Cw7	41	EGDCAPEEK	212-220	lentivirus-dendritic cells	Breckpot, 2004	Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691)
MAGE-A3		DP4	75	RKVAELVHFLLLKYR	111-125	peptide	Cesson, 2011	Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101)
MAGE-A3		DR1	18	ACYEFLWGPRALVETS	267-282	protein	Zhang, 2003	Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol. 2003 Jul 1, 171(1):219-25. (PMID: 12817001)
MAGE-A2		DR13	19	LLKYRAREPVTKAE	121-134	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-A3		DQ6	63	KKLLTQHFVQENYLEY	243-258	peptide	Schultz, 2004	Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol. 2004 Jan 15, 172(2):1304-10. (PMID: 14707109)
MAGE-A2		B37	3	REPVTKAEML	127-136	autologous tumor cells	Tanzarella, 1999	Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990)
MAGE-A3		A2	44	FLWGPRALV	271-279	peptide	van der Bruggen, 1994	van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec, 24(12):3038-43. (PMID: 7805731)	Only processed by the intermediate proteasome beta5i.
MAGE-A3		A24	20	VAELVHFLL	113-121	peptide	Miyagawa, 2006	Miyagawa N1, Kono K, Mimura K, Omata H, Sugai H, Fujii H. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology. 2006, 70(1):54-62. (PMID: 16446550)
MAGE-A3		DR4	24	RKVAELVHFLLLKYR	111-125	peptide	Cesson, 2010	Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101)
MAGE-A3		DR4	24	VIFSKASSSLQL	149-160	peptide	Kobayashi, 2001	Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001 Jun 15, 61(12):4773-8. (PMID: 11406551)
MAGE-A3		DR7	25	VIFSKASSSLQL	149-160	peptide	Kobayashi, 2001	Kobayashi H, Song Y, Hoon DS, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res. 2001 Jun 15, 61(12):4773-8. (PMID: 11406551)
MAGE-A3		DR11	25	GDNQIMPKAGLLIIV	191-205	peptide	Consogno, 2003	Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood. 2003 Feb 1, 101(3):1038-44. (PMID: 12393675)
MAGE-A3		DR7	25	VFGIELMEVDPIGHL	161-175	peptide	Cesson, 2011	Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother. 2011 Jan, 60(1):23-35. (PMID: 20857101)
MAGE-A3		DR11	25	TSYVKVLHHMVKISG	281-295	protein	Manici, 1999	Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999 Mar 1, 189(5):871-6. (PMID: 10049951)
MAGE-A3		DR13	19	RKVAELVHFLLLKYRA	111-126	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-A3		DR13	19	FLLLKYRAREPVTKAE	119-134	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-A4		A2	44	GVYDGREHTV	230-239	adeno-dendritic cells	Duffour, 1999	Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol. 1999 Oct, 29(10):3329-37.
MAGE-A4		A1	26	EVDPASNTY	169-177	peptide after tetramer sorting	Kobayashi, 2003	Kobayashi T, Lonchay C, Colau D, Demotte N, Boon T, van der Bruggen P. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens. 2003 Nov, 62(5):426-32. (PMID: 14617050)	This peptide is encoded by allele MAGE-4a, which is expressed in one third of MAGE-4 positive tumor samples. The other allele, namely MAGE-4b, encodes peptide EVDPTSNTY.
MAGE-A6		B35	20	EVDPIGHVY	168-176	autologous tumor cells	Benlalam, 2003	Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146)
MAGE-A6		Cw7	41	EGDCAPEEK	212-220	lentivirus-dendritic cells	Breckpot, 2004	Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691)
MAGE-A4		A24	20	NYKRCFPVI	143-151	peptide	Ottaviani, 2006	Ottaviani S1, Colau D, van der Bruggen P, van der Bruggen P. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells. Cancer Immunol Immunother. 2006 Jul, 55(7):867-72. (PMID: 16151806)
MAGE-A6		DR13	19	LLKYRAREPVTKAE	121-134	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-A6		Cw16	7	ISGGPRISY	293-301	autologous tumor cells	Vantomme, 2003	Vantomme V, Boël P, De PlaenE , Boon T, van der Bruggen P. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16. 2003 January.
MAGE-A6		A34	1	MVKISGGPR	290-298	autologous tumor cells	Zorn, 1999	Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol. 1999 Feb, 29(2):602-7. (PMID: 10064076)
MAGE-A10		A2	44	GLYDGMEHL	254-262	autologous tumor cells	Huang, 1999	Huang LQ, Brasseur F, Serrano A, De Plaen E, van der Bruggen P, Boon T, Van Pel A. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol. 1999 Jun 1, 162(11):6849-54. (PMID: 10352307)	Only processed by the intermediate proteasome beta1ibeta51.
MAGE-A6		B37	3	REPVTKAEML	127-136	autologous tumor cells	Tanzarella, 1999	Tanzarella S, Russo V, Lionello I, Dalerba P, Rigatti D, Bordignon C, Traversari C. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. Cancer Res. 1999 Jun 1, 59(11):2668-74. (PMID: 10363990)
MAGE-A4		A24	20	NYKRCFPVI	143-151	peptide	Miyahara, 2005	Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res. 2005 Aug 1, 11(15):5581-9. (PMID: 16061876)
MAGE-A4		B37	3	SESLKMIF	156-163	poxvirus-dendritic cells	Zhang, 2002	Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens. 2002 Nov, 60(5):365-71. (PMID: 12492812)
MAGE-A10		B53	2	DPARYEFLW	290-298	poxvirus-de]ndritic cells	Chaux, 1999	Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 1999 Sep 1, 163(5):2928-36. (PMID: 10453041)
MAGE-A12 m		A2	44	FLWGPRALV	271-279	peptide	van der Bruggen, 1994	van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994 Dec, 24(12):3038-43. (PMID: 7805731)	Same peptide as MAGE-A3/A2 (aa 271-279). Incompletely spliced transcript found only in melanomas.
MAGE-A12 m		Cw7	41	VRIGHLYIL	170-178	autologous tumor cells	Heidecker, 2000	Heidecker L, Brasseur F, Probst-Kepper M, Guéguen M, Boon T, Van den Eynde BJ. Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12. J Immunol. 2000 Jun 1, 164(11):6041-5. (PMID: 10820289)
MAGE-A12 m		Cw7	41	VRIGHLYIL	170-178	autologous tumor cells	Panelli, 2000	Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol. 2000 Apr 15, 164(8):4382-92. (PMID: 10754339)
MAGE-A12 m		DP4	75	REPFTKAEMLGSVIR	127-141	peptide	Wang, 2007	Wang XF, Cohen WM, Castelli FA, Almunia C, Lethé B, Pouvelle-Moratille S, Munier G, Charron D, Ménez A, Zarour HM, van der Bruggen P, Busson M, Maillère B. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol Immunother. 2007 Jun, 56(6):807-18. (PMID: 16988823)
MAGE-A12 m		Cw7	41	EGDCAPEEK	212-220	lentivirus-dendritic cells	Breckpot, 2004	Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004 Feb 15, 172(4):2232-7. (PMID: 14764691)
MAGE-A12 m		DR13	19	AELVHFLLLKYRAR	114-127	protein	Chaux, 1999	Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med. 1999 Mar 1, 189(5):767-78. (PMID: 10049940)
MAGE-C1		A2	44	ILFGISLREV	959-968	peptide	Anderson, 2011	Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011 Jul, 60(7):985-97. (PMID: 21461886)
MAGE-C1		DQ6	63	SSALLSIFQSSPE	137-149	peptide	Nuber, 2010	Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919)
MAGE-C1		A2	44	KVVEFLAML	1083-1091	peptide	Anderson, 2011	Anderson LD Jr, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011 Jul, 60(7):985-97. (PMID: 21461886)
MAGE-C2		A2	44	ALKDVEERV	336-344	autologous tumor cells	Ma, 2004	Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer. 2004 May 1, 109(5):698-702. (PMID: 14999777)
MAGE-C1		DR15	20	VSSFFSYTL	779-787	peptide	Nuber, 2010	Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919)
MAGE-C1		DQ6	63	SFSYTLLSL	450-458	peptide	Nuber, 2010	Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010 Aug 24, 107(34):15187-92. (PMID: 20696919)
MAGE-C2		B44	21	SESIKKKVL	307-315	autologous tumor cells	Godelaine, 2007	Godelaine D, Carrasco J, Brasseur F, Neyns B, Thielemans K, Boon T, Van Pel A. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother. 2007 Jun, 56(6):753-9. (56(6):753-9.)
MAGE-C2		A2	44	LLFGLALIEV	191-200	autologous tumor cells	Ma, 2004	Ma W, Germeau C, Vigneron N, Maernoudt AS, Morel S, Boon T, Coulie PG, Van den Eynde BJ. Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer. 2004 May 1, 109(5):698-702. (PMID: 14999777)
MAGE-C2		DR15	20	SSTLYLVFSPSSFST	43-57	peptide	Wen, 2011	Wen W, Zhang L, Peng J, Chen J, Hao J, Li X, Qian X, Zeng P, Zhang Y, Yin Y. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587. Cancer Sci. 2011 Aug, 102(8):1455-61. (PMID: 21595801)
mucin			0	PDTRPAPGSTAPPAHGVTSA		transfected B cells	Jerome, 1993		MHC-unrestricted recognition by CTL of a repeated motif that is unmasked in tumors due to mucin underglycosylation. Mucin underglycosylation also occurs in breast duct epithelial cells during lactation, but only at the extracellular apical surface, which is not accessible to T cells.
MAGE-C2		B57	8	ASSTLYLVF	42-50	autologous tumor cells	Ma, 2011	Ma W1, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ. A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy. Int J Cancer. 2011 Nov 15, 129(10):2427-34. (PMID: 21207413)
NY-ESO-1 / LAGE-2		A2	44	SLLMWITQC	157-165	autologous tumor cells	Jäger, 1998	Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998 Jan 19, 187(2):265-70. (PMID: 9432985)
NY-ESO-1 / LAGE-2		A2	44	SLLMWITQC	157-165	autologous tumor cells	Chen, 2000	Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A, Old LJ, Cerundolo V. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol. 2000 Jul 15, 165(2):948-55. (PMID: 10878370)
NY-ESO-1 / LAGE-2		A2	44	SLLMWITQC	157-165	autologous tumor cells	Valmori, 2000	Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000 Aug 15, 60(16):4499-506. (PMID: 10969798)
NY-ESO-1 / LAGE-2		A2	44	MLMAQEALAFL	ORF2	autologous tumor cells	Aarnoudse, 1999	Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963)
NY-ESO-1 / LAGE-2		A2	44	MLMAQEALAFL	(1-11)	autologous tumor cells	Aarnoudse, 1999	Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer. 1999 Jul 30, 82(3):442-8. (PMID: 10399963)
NY-ESO-1 / LAGE-2		A24	20	YLAMPFATPME	91-101	peptide	Eikawa, 2013	Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530)
NY-ESO-1 / LAGE-2		A31	5	ASGPGGGAPR	53-62	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882)
NY-ESO-1 / LAGE-2		A31	5	LAAQERRVPR	ORF2	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882)
NY-ESO-1 / LAGE-2		A31	5	LAAQERRVPR	(18-27)	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998 Oct 1, 161(7):3598-606. (PMID: 9759882)
NY-ESO-1 / LAGE-2		A68	8	TVSGNILTIR	127-136	mRNA-transfected cells	Matsuzaki, 2008	Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother. 2008 Aug, 57(8):1185-95. (PMID: 18253733)
NY-ESO-1 / LAGE-2		B7	17	APRGPHGGAASGL	60-72	peptide	Ebert, 2009	Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res. 2009 Feb 1, 69(3):1046-54. (PMID: 19176376)
NY-ESO-1 / LAGE-2		B35	20	MPFATPMEAEL	94-104	peptide	Eikawa, 2013	Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530)
NY-ESO-1 / LAGE-2		B49	0	KEFTVSGNILTI	124-135	mRNA-transfected cells	Knights, 2009	Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009 Mar, 58(3):325-38. (PMID: 18663444)
NY-ESO-1 / LAGE-2		B52	5	FATPMEAEL	96-104	peptide	Eikawa, 2013	Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530)
NY-ESO-1 / LAGE-2		Cw3	17	LAMPFATPM	92-100	adenovirus-PBMC	Gnjatic, 2000	Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A. 2000 Sep 26, 97(20):10917-22. (PMID: 11005863)
NY-ESO-1 / LAGE-2		DP4	75	SLLMWITQCFLPVF	157-170	peptide	Zeng, 2001	Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001 Mar 27, 98(7):3964-9. (PMID: 11259659)
NY-ESO-1 / LAGE-2		DR1	18	LLEFYLAMPFATPMEAELARRSLAQ	87-111	peptide	Mandic, 2005	Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941)
NY-ESO-1 / LAGE-2		DP4	75	LLEFYLAMPFATPMEAELARRSLAQ	87-111	peptide	Mandic, 2005	Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941)
NY-ESO-1 / LAGE-2		DR1	18	EFYLAMPFATPM	89-100	protein	Chen, 2004	Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A. 2004 Jun 22, 101(25):9363-8. (PMID: 15197261)
NY-ESO-1 / LAGE-2		DR1	18	PGVLLKEFTVSGNILTIRLTAADHR	119-143	peptide	Ayyoub, 2010	Ayyoub M1, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res. 2010 Sep 15, 16(18):4607-15. (PMID: 20670945)
NY-ESO-1 / LAGE-2		DR3	21	QGAMLAAQERRVPRAAEVPR	ORF2	protein	Slager, 2004	Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093)
NY-ESO-1 / LAGE-2		DR2	25	RLLEFYLAMPFA	86-97	protein	Chen, 2004	Chen Q1, Jackson H, Parente P, Luke T, Rizkalla M, Tai TY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, Maraskovsky E, Green S, Miloradovic L, McCluskey J, Old LJ, Davis ID, Cebon J, Chen W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A. 2004 Jun 22, 101(25):9363-8. (PMID: 15197261)
NY-ESO-1 / LAGE-2		DR3	21	QGAMLAAQERRVPRAAEVPR	(14-33)	protein	Slager, 2004	Slager EH, van der Minne CE, Krüse M, Krueger DD, Griffioen M, Osanto S. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes. J Immunol. 2004 Apr 15, 172(8):5095-102. (PMID: 15067093)
NY-ESO-1 / LAGE-2		Cw6	18	ARGPESRLL	80-88	adenovirus-PBMC	Gnjatic, 2000	Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A. 2000 Sep 26, 97(20):10917-22. (PMID: 11005863)	Only processed by the intermediate proteasome beta5i.
NY-ESO-1 / LAGE-2		C12	12	FATPMEAELAR	96-106	peptide	Eikawa, 2013	Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013 Jan 15, 132(2):345-54. (PMID: 22729530)
NY-ESO-1 / LAGE-2		B51	12	MPFATPMEA	94-102	adenovirus-APC	Jäger, 2002	Jäger D, Unkelbach M, Frei C, Bert F, Scanlan M, Jäger E, Old L, Chen Y, Knuth A. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. 2002 January.
NY-ESO-1 / LAGE-2		DR4	24	PFATPMEAELARR	95-107	peptide	Mizote, 2010	Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979)
NY-ESO-1 / LAGE-2		DR4	24	PGVLLKEFTVSGNILTIRLT	119-138	peptide and protein	Jäger, 2000	Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854)
NY-ESO-1 / LAGE-2		DR4	24	PGVLLKEFTVSGNILTIRLT	119-138	peptide and protein	Zarour, 2000	Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res. 2000 Sep 1, 60(17):4946-52. (PMID: 10987311)
NY-ESO-1 / LAGE-2		DR4	24	VLLKEFTVSG	121-130	peptide	Zeng, 2000	Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 2000 Jul 15, 165(2):1153-9. (PMID: 10878395)
NY-ESO-1 / LAGE-2		DR4	24	AADHRQLQLSISSCLQQL	139-156	protein	Jäger, 2000	Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med. 2000 Feb 21, 191(4):625-30. (PMID: 10684854)
NY-ESO-1 / LAGE-2		DR4	24	LLEFYLAMPFATPMEAELARRSLAQ	87-111	peptide	Mandic, 2005	Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941)
NY-ESO-1 / LAGE-2		DR52b	25	LKEFTVSGNILTIRL	123-137	protein	Bioley, 2009	Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res. 2009 Jul 1, 15(13):4467-74. (PMID: 19531622)
NY-ESO-1 / LAGE-2		DR7	25	PGVLLKEFTVSGNILTIRLTAADHR	119-143	peptide	Zarour, 2002	Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 Jan 1, 62(1):213-8. (PMID: 11782380)
NY-ESO-1 / LAGE-2		DR7	25	LLEFYLAMPFATPMEAELARRSLAQ	87-111	peptide	Mandic, 2005	Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol. 2005 Feb 1, 174(3):1751-9. (PMID: 15661941)
NY-ESO-1 / LAGE-2		DR8	4	KEFTVSGNILT	124-134	peptide	Mizote, 2010	Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979)
NY-ESO-1 / LAGE-2		DR9	3	LLEFYLAMPFATPM	87-100	peptide	Mizote, 2010	Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine. 2010 Jul 19, 28(32):5338-46. (PMID: 20665979)
NY-ESO-1 / LAGE-2		DR15	20	AGATGGRGPRGAGA	37-50	protein	Hasegawa, 2006	Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006 Mar 15, 12(6):1921-7. (PMID: 16551878)
SAGE		A24	20	LYATVIHDI	715-723	peptide	Miyahara, 2005	Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res. 2005 Aug 1, 11(15):5581-9. (PMID: 16061876)
Sp17		A1	26	ILDSSEEDK	103-111	protein	Chiriva-Internati, 2003	Chiriva-Internati M, Wang Z, Pochopien S, Salati E, Lim SH. Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer. 2003 Dec 10, 107(5):863-5. (PMID: 14566839)
SSX-2		A2	44	KASEKIFYV	41-49	autologous tumor cells	Ayyoub, 2002	Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol. 2002 Feb 15, 168(4):1717-22. (PMID: 11823502)
SSX-2		DP1	14	EKIQKAFDDIAKYFSK	19-34	peptide	Ayyoub, 2004	Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC, Valmori D. Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol. 2004 Jun 1 , 172(11):7206-11. (PMID: 15153546)
SSX-2		DR1	18	FGRLQGISPKI	101-111	peptide	Neumann, 2011	Neumann F, Kubuschok B, Ertan K, Schormann C, Stevanovic S, Preuss KD, Schmidt W, Pfreundschuh M. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses. Cancer Immunol Immunother. 2011 Sep, 60(9):1333-46. (PMID: 21630107)
SSX-2		DR3	21	WEKMKASEKIFYVYMKRK	37-54	peptide	Ayyoub, 2005	Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol. 2005 Jan, 114(1):70-8. (PMID: 15596411)
SSX-2		DR4	24	KIFYVYMKRKYEAMT	45-59	peptide]	Neumann, 2004	Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer. 2004 Nov 20, 112(4):661-8. (PMID: 15382048)
SSX-2		DR11	25	KIFYVYMKRKYEAM	45-58	protein	Ayyoub, 2004	Ayyoub M1, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest. 2004 Apr, 113(8):1225-33. (PMID: 15085202)
TRP2-INT2		A68	8	EVISCKLIKR	intron 2	autologous tumor cells	Lupetti, 1998	Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med. 1998 Sep 21, 188(6):1005-16. (PMID: 9743519)	Incompletely spliced transcript found only in melanomas.
NY-ESO-1/LAGE-2		DR7	25	LLEFYLAMPFATPM	87-99		Costa Nunes, 2019	Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C. High-throughput screening of human tumor antigen–specific CD4 T cells, including neoantigen-reactive T cells. Clin Cancer Res. 2019 Jul 15, 25(14):4320-4331. (PMID: 31015344)
LRPAP1		A2	44	FLGPWAAS	21-30	peptide	Marijt, 2019	Marijt KA, Blijleven L, Verdegaal EME, Kester MG, Kowalewski DJ, Rammensee HG, Stevanović S, Heemskerk MHM, van der Burg SH, van Hall T. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med. 2018 Sep 3, 215(9):2325-2337. (PMID: 30115740)	TAP-independent processing pathway
CT37/FMR1NB		A2	44	YLCSGSSYFV	89-98	peptide	Flores-Villanueva, 2018
Cyclin-A1		A2	44	SLMEPPAVLLL	410-420	Peptide	Teck, 2020	Teck AT, Urban S, Quass P, Nelde A, Schuster H, Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2020 Jul 69(7):1217-1227. (PMID: 32157447

Gene/Protein ⓘ	Normal/Tumor ⓘ	HLA ⓘ	HLA% ⓘ	Peptide Sequence	Position ⓘ	Lymphocyte Stimulation ⓘ	Reference ⓘ	Full Reference	Note	Note ⓘ
gp100 / Pmel17	melanoma	A2	44	KTWGQYWQV	154-162	autologous tumor cells	Bakker, 1995	Bakker AB, Schreurs MW, Tafazzul G, de Boer AJ, Kawakami Y, Adema GJ, Figdor CG. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer. 1995 Jul 4, 62(1):97-102. (PMID: 7541395)
gp100 / Pmel17	melanoma	A2	44	(A)MLGTHTMEV	177(8)-186	peptide	Tsai, 1997	Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997 Feb 15, 158(4):1796-802. (PMID: 9029118)
gp100 / Pmel17	melanoma	A2	44	KTWGQYWQV	154-163	autologous tumor cells	Kawakami, 1995	Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734)
gp100 / Pmel17	melanoma	A2	44	ITDQVPFSV	209-217	autologous tumor cells	Kawakami, 1995	Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734)
gp100 / Pmel17	melanoma	A2	44	YLEPGPVTA	280-288	autologous tumor cells	Cox, 1994	Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994 Apr 29, 264(5159):716-9. (PMID: 7513441)
gp100 / Pmel17	melanoma	A2	44	VLYRYGSFSV	476-485	autologous tumor cells	Kawakami, 1995	Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995 Apr 15, 154(8):3961-8. (PMID: 7706734)
gp100 / Pmel17	melanoma	A2	44	LLDGTATLRL	457-466	autologous tumor cells	Kawakami, 1994	Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994 Jul 5, 91(14):6458-62. (PMID: 8022805)
gp100 / Pmel17	melanoma	A2	44	RLMKQDFSV	619-627	autologous tumor cells	Kawakami, 1998	Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734)
gp100 / Pmel17	melanoma	A2	44	SLADTNSLAV	570-579	peptide	Tsai, 1997	Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol. 1997 Feb 15, 158(4):1796-802. (PMID: 9029118)
gp100 / Pmel17	melanoma	A3	22	LIYRRRLMK	614-622	autologous tumor cells	Kawakami, 1998	Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734)
gp100 / Pmel17	melanoma	A2	44	RLPRIFCSC	639-647	autologous tumor cells	Kawakami, 1998	Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734)
gp100 / Pmel17	melanoma	A3	22	IALNFPGSQK	86-95	peptide	Kawashima, 1998	Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143)
gp100 / Pmel17	melanoma	A3	22	ALLAVGATK	17-25	autologous tumor cells	Skipper, 1996	Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL Jr. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol. 1996 Dec 1, 157(11):5027-33. (PMID: 8943411)
gp100 / Pmel17	melanoma	A3	22	RSYVPLAHR	195-202 and 191 or 192e	autologous tumor cells	Michaux, 2014	Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J Immunol. 2014 Feb 15, 192(4):1962-71. (PMID: 24453253)
gp100 / Pmel17	melanoma	A3	22	ALNFPGSQK	87-95	peptide	Kawashima, 1998	Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143)
gp100 / Pmel17	melanoma	A24	20	VYFFLPDHL	intron 4	autologous tumor cells	Robbins, 1997	Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 1997 Jul 1, 159(1):303-8. (PMID: 9200467)
gp100 / Pmel17	melanoma	A11	13	ALNFPGSQK	87-95	peptide	Kawashima, 1998	Kawashima I, Tsai V, Southwood S, Takesako K, Celis E, Sette A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer. 1998 Nov 9, 78(4):518-24. (PMID: 9797143)
gp100 / Pmel17	melanoma	B7	17	SSPGCQPPA	529-537	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
gp100 / Pmel17	melanoma	A68	8	HTMEVTVYHR	182-191	autologous tumor cells	Sensi, 2002	Sensi M, Pellegatta S, Vegetti C, Nicolini G, Parmiani G, Anichini A. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. Tissue Antigens. 2002 Apr, 59(4):273-9. (PMID: 12135425)
gp100 / Pmel17	melanoma	A32	8	RTKQLYPEW	40-42 and 47-52	autologous tumor cells	Vigneron, 2004	Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S, van der Bruggen P, Boon T, Van den Eynde BJ. An antigenic peptide produced by peptide splicing in the proteasome. Science. 2004 Apr 23, 304(5670):587-90. (PMID: 15001714)
gp100 / Pmel17	melanoma	B35	20	VPLDCVLYRY	471-480	autologous tumor cells	Benlalam, 2003	Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146)
gp100 / Pmel17	melanoma	DQ6	63	GRAMLGTHTMEVTVY	175-189	peptide	Kobayashi, 2001	Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001 Oct 15, 61(20):7577-84. (PMID: 11606397)
gp100 / Pmel17	melanoma	DR4	24	WNRQLYPEWTEAQRLD	44-59	peptide	Touloukian, 2000	Touloukian CE, Leitner WW, Topalian SL, Li YF, Robbins PF, Rosenberg SA, Restifo NP. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000 Apr 1, 164(7):3535-42. (PMID: 10725708)
gp100 / Pmel17	melanoma	B35	20	LPHSSSHWL	630-638	autologous tumor cells	Vigneron, 2005	Vigneron N, Ooms A, Morel S, Ma W, Degiovanni G, Van den Eynde BJ. A peptide derived from melanocytic protein gp100 and presented by HLA-B35 is recognized by autologous cytolytic T lymphocytes on melanoma cells. Tissue Antigens. 2005 Feb, 65(2):156-62. (PMID: 15713214)
gp100 / Pmel17	melanoma	DR7	25	TTEWVETTARELPIPEPE	420-437	protein	Parkhurst, 2004	Parkhurst MR, Riley JP, Robbins PF, Rosenberg SA. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein. J Immunother. 2004 Mar-Apr, 27(2):79-91. (PMID: 14770079)
gp100 / Pmel17	melanoma	DR7	25	TGRAMLGTHTMEVTVYH	174-190	retrovirus - dendritic cells	Lapointe, 2001	Lapointe R, Royal RE, Reeves ME, Altomare I, Robbins PF, Hwu P. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol. 2001 Oct 15, 167(8):4758-64. (PMID: 11591807)
gp100 / Pmel17	melanoma	DR53	49	GRAMLGTHTMEVTVY	175-189	peptide	Kobayashi, 2001	Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001 Oct 15, 61(20):7577-84. (PMID: 11606397)
gp100 / Pmel17	melanoma	Cw8	7	SNDGPTLI	71-78	autologous tumor cells	Castelli, 1999	Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol. 1999 Feb 1, 162(3):1739-48. (PMID: 9973437)
CEA	gut carcinoma	A2	44	YLSGANLNL	605-613	peptide	Tsang, 1995	Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995 Jul 5, 87(13):982-90. (PMID: 7629885)
CEA	gut carcinoma	A24	20	TYACFVSNL	652-660	peptide	Nukaya, 1999	Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999 Jan 5, 80(1):92-7. (PMID: 9935237)
CEA	gut carcinoma	A2	44	GVLVGVALI	694-702	peptide	Alves, 2007	Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, Vuilleumier H, Kruger T, Givel JC, Lévy F, Speiser DE, Cerottini JC, Romero P. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother. 2007 Nov, 56(11):1795-805. (PMID: 17447064)
CEA	gut carcinoma	DR7	25	TYYRPGVNLSLSC	425-437	peptide	Crosti, 2006	Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607)
CEA	gut carcinoma	DR4	24	YSWRINGIPQQHTQV	625-639	peptide	Ruiz, 2004	Ruiz M, Kobayashi H, Lasarte JJ, Prieto J, Borrás-Cuesta F, Celis E, Sarobe P. Identification and characterization of a T-helper peptide from carcinoembryonic antigen. Clin Cancer Res. 2004 Apr 15, 10(8):2860-7. (PMID: 15102695)
CEA	gut carcinoma	DR9	3	YACFVSNLATGRNNS	653-667	peptide	Kobayashi, 2002	Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borras-Cuesta F, Celis E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res. 2002 Oct, 8(10):3219-25. (PMID: 12374692)
CEA	gut carcinoma	DR7	25	EIIYPNASLLIQN	99-111	peptide	Crosti, 2006	Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607)
CEA	gut carcinoma	DR11	25	LWWVNNQSLPVSP	177-189 and 355-367	peptide	Campi, 2003	Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013)
CEA	gut carcinoma	DR13	19	LWWVNNQSLPVSP	177-189 and 355-367	peptide	Campi, 2003	Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013)
CEA	gut carcinoma	DR14	6	LWWVNNQSLPVSP	177-189 and 355-367	peptide	Campi, 2003	Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res. 2003 Dec 1, 63(23):8481-6. (PMID: 14679013)
CEA	gut carcinoma	DR3	21	AYVCGIQNSVSANRS	568-582	peptide	Crosti, 2006	Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607)
CEA	gut carcinoma	DR14	6	EIIYPNASLLIQN	99-111	peptide	Crosti, 2006	Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607)
CEA	gut carcinoma	DR14	6	NSIVKSITVSASG	666-678	peptide	Crosti, 2006	Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP. Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol. 2006 Apr 15, 176(8):5093-9. (PMID: 16585607)
CEA	gut carcinoma	A3	22	HLFGYSWYK	61-69	peptide	Kawashima, 1999	Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999 Jan 15, 59(2):431-5. (PMID: 9927058)
CEA	gut carcinoma	A24	20	QYSWFVNGTF	268-277	peptide	Nukaya, 1999	Nukaya I, Yasumoto M, Iwasaki T, Ideno M, Sette A, Celis E, Takesako K, Kato I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer. 1999 Jan 5, 80(1):92-7. (PMID: 9935237)
CEA	gut carcinoma	A2	44	IMIGVLVGV	691-699	peptide	Kawashima, 1998	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234)
CEA	gut carcinoma	DR4	24	DTGFYTLHVIKSDLVNEEATGQFRV	116-140	peptide	Shen, 2004	Shen L1, Schroers R, Hammer J, Huang XF, Chen SY. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother. 2004 May, 53(5):391-403. (PMID: 14624313)
mammaglobin-A	breast cancer	A3	22	PLLENVISK	23-31	peptide	Jaramillo, 2002	Jaramillo A, Majumder K, Manna PP, Fleming TP, Doherty G, Dipersio JF, Mohanakumar T. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer. 2002 Dec 10, 102(5):499-506. (PMID: 12432553)
Melan-A / MART-1	melanoma	A2	44	ILTVILGVL	32-40	autologous tumor cells	Castelli, 1995	Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med. 1995 Jan 1, 181(1):363-8. (PMID: 7807017 )
Melan-A / MART-1	melanoma	A2	44	(E)AAGIGILTV	26(27)-35	autologous tumor cells	Kawakami, 1994	Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med. 1994 Jul 1, 180(1):347-52. (PMID: 7516411)
Melan-A / MART-1	melanoma	B45	2	AEEAAGIGIL(T)	24-33(34)	autologous tumor cells	Schneider, 1998	Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde KH, Wölfel T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer. 1998 Jan 30, 75(3):451-8. (PMID: 9455808)
Melan-A / MART-1	melanoma	Cw7	41	RNGYRALMDKS	51-61	peptide	Larrieu, 2008	Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother. 2008 May, 57(5):745-52. (PMID: 18097665)
Melan-A / MART-1	melanoma	B35	20	EAAGIGILTV	26-35	autologous tumor cells	Benlalam, 2003	Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146)
Melan-A / MART-1	melanoma	DP5	3	YTTAEEAAGIGILTVILGVLLLIGCWYCRR	21-50	peptide	Meng, 2011	Meng Z, Wang Y, Zhang G, Ke Y, Yan Y, Wu L, Huang Q, Zeng G, Wang Y, Ying H, Jiao S. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations. J Immunother. 2011 Sep, 34(7):525-34. (PMID: 21760531)
Melan-A / MART-1	melanoma	DQ6	63	EEAAGIGILTVI	25-36	peptide	Bioley, 2006	Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590)
Melan-A / MART-1	melanoma	DR1	18	APPAYEKLpSAEQf	100-111	peptide	Depontieu, 2009	Depontieu FR, Qian J, Zarling AL, McMiller TL, Salay TM, Norris A, English AM, Shabanowitz J, Engelhard VH, Hunt DF, Topalian SL. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A. 2009 Jul 21, 106(29):12073-8. (PMID: 19581576)
Melan-A / MART-1	melanoma	DR1	18	AAGIGILTVILGVL	27-40	peptide	Bioley, 2006	Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590)
Melan-A / MART-1	melanoma	DR4	24	RNGYRALMDKSLHVGTQCALTRR	51-73	peptide	Zarour, 2000	Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A. 2000 Jan 4, 97(1):400-5. (PMID: 10618430)
Melan-A / MART-1	melanoma	DR3	21	EEAAGIGILTVI	25-36	peptide	Bioley, 2006	Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol. 2006 Nov 15, 177(10):6769-79. (PMID: 17082590)
Melan-A / MART-1	melanoma	DR52	41	KNCEPVVPNAPPAYEKLSAE	91-110	peptide	Godefroy, 2006	Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol. 2006 Oct, 121(1):54-62. (PMID: 16814609)
Melan-A / MART-1	melanoma	DR11	25	MPREDAHFIYGYPKKGHGHS	20-Jan	peptide	Godefroy, 2006	Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin Immunol. 2006 Oct, 121(1):54-62. (PMID: 16814609)
OA1	melanoma	A24	20	LYSACFWWL	126-134	peptide	Touloukian, 2003	Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, Sette A, Rosenberg SA, Restifo NP. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol. 2003 Feb 1, 170(3):1579-85. (PMID: 12538723)
PAP	prostate cancer	A2	44	TLMSAMTNL	112-120	peptide	Olson, 2010	Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431)
PAP	prostate cancer	A2	44	ALDVYNGLL	299-307	peptide	Olson, 2010	Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431)
PAP	prostate cancer	A2	44	FLFLLFFWL	18-26	peptide	Olson, 2010	Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother. 2010 Jun, 59(6):943-53. (PMID: 20140431)
NY-BR-1	breast cancer	A2	44	SLSKILDTV	904-912	peptide	Wang, 2006	Wang W, Epler J, Salazar LG, Riddell SR. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res. 2006 Jul 1, 66(13):6826-33. (PMID: 16818660)
PSA	prostate carcinoma	A2	44	FLTPKKLQCV	165-174	peptide	Correale, 1997	Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19, 89(4):293-300. (PMID: 9048833)
PSA	prostate carcinoma	A2	44	VISNDVCAQV	178-187	peptide	Correale, 1997	Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst. 1997 Feb 19, 89(4):293-300. (PMID: 9048833)
TRP-1 / gp75	melanoma	A31	5	MSLQRQFLR	alt. ORF	autologous tumor cells	Wang, 1996	Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med. 1996 Mar 1, 183(3):1131-40. (PMID: 8642255)
RAB38 / NY-MEL-1	melanoma	A2	44	VLHWDPETV	50-58	peptide	Walton, 2006	Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Lévy F, Knuth A, Jäger D, Zippelius A. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol. 2006 Dec 1, 177(11):8212-8. (PMID: 17114498)
TRP-1 / gp75	melanoma	DR4	24	ISPNSVFSQWRVVCDSLEDYD	277-297	peptide	Touloukian, 2002	Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, Hwu P, Rosenberg SA, Restifo NP. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 2002 Sep 15, 62(18):5144-7. (PMID: 12234976)
TRP-1 / gp75	melanoma	DR15	20	SLPYWNFATG	245-254	autologous tumor cells	Robbins, 2002	Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol. 2002 Nov 15, 169(10):6036-47. (PMID: 12421991)
TRP-2	melanoma	A2	44	SVYDFFVWL	180-188	peptide	Parkhurst, 1998	Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998 Nov 1, 58(21):4895-901. (PMID: 9809996)
TRP-2	melanoma	A2	44	TLDSQVMSL	360-368	peptide	Noppen, 2000	Noppen C, Lévy F, Burri L, Zajac P, Remmel E, Schaefer C, Lüscher U, Heberer M, Spagnoli GC. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer. 2000 Jul 15, 87(2):241-6. (PMID: 10861482)
TRP-2	melanoma	A31	5	LLGPGRPYR	197-205	autologous tumor cells	Wang, 1996	Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996 Dec 1, 184(6):2207-16. (PMID: 8976176)
TRP-1 / gp75	melanoma	DR17	21	SQWRVVCDSLEDYDT	284-298	peptide	Osen, 2010	Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries. PLoS One. 2010 Nov 30, 5(11):e14137 (PMID: 21152437)
TRP-2	melanoma	A31	5	LLGPGRPYR	197-205	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998 Jan 15, 160(2):890-7. (PMID: 9551926)
TRP-2	melanoma	Cw8	7	ANDPIFVVL	387-395	autologous tumor cells	Castelli, 1999	Castelli C, Tarsini P, Mazzocchi A, Rini F, Rivoltini L, Ravagnani F, Gallino F, Belli F, Parmiani G. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J Immunol. 1999 Feb 1, 162(3):1739-48. (PMID: 9973437)
TRP-2	melanoma	A33	5	LLGPGRPYR	197-205	autologous tumor cells	Wang, 1998	Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998 Jan 15, 160(2):890-7. (PMID: 9551926)
TRP-2	melanoma	DR3	21	QCTEVRADTRPWSGP	60-74	peptide	Paschen, 2005	Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res. 2005 Jul 15, 11(14):5241-7. (PMID: 16033842)
TRP-2	melanoma	DR15	20	ALPYWNFATG	241-250	autologous tumor cells	Robbins, 2002	Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J Immunol. 2002 Nov 15, 169(10):6036-47. (PMID: 12421991)
tyrosinase	melanoma	A1	26	KCDICTDEY	243-251	autologous tumor cells	Kittlesen, 1998	Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol. 1998 Mar 1, 160(5):2099-106. (PMID: 9498746)
tyrosinase	melanoma	A1	26	SSDYVIPIGTY	146-156	autologous tumor cells	Kawakami, 1998	Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol. 1998 Dec 15, 161(12):6985-92. (PMID: 9862734)
tyrosinase	melanoma	A2	44	MLLAVLYCL	1-9	autologous tumor cells	Wölfel, 1994	Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994 Mar, 24(3):759-64. (PMID: 8125142)
tyrosinase	melanoma	A2	44	CLLWSFQTSA	8-17	peptide	Riley, 2001	Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J Immunother. 2001 May-Jun, 24(3):212-20. (PMID: 11394498)
tyrosinase	melanoma	A2	44	YMDGTMSQV	369-377	autologous tumor cells	Wölfel, 1994	Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde KH, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994 Mar, 24(3):759-64. (PMID: 8125142)
tyrosinase	melanoma	A2	44	YMDGTMSQV	369-377	autologous tumor cells	Skipper, 1996	Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 1996 Feb 1, 183(2):527-34. (PMID: 8627164)
tyrosinase	melanoma	A24	20	IYMDGTADFSF	368-373 and 336-340e	autologous tumor cells	Dalet, 2011	Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A. 2011 Jul 19, 108(29):E323-31. (PMID: 21670269)
tyrosinase	melanoma	A24	20	AFLPWHRLF	206-214	autologous tumor cells	Kang, 1995	Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 1995 Aug 1, 155(3):1343-8. (PMID: 7543520)
tyrosinase	melanoma	A26	8	QCSGNFMGF	90-98	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
tyrosinase	melanoma	B35	20	LPSSADVEF	312-320	autologous tumor cells	Morel, 1999	Morel S, Ooms A, Van Pel A, Wölfel T, Brichard VG, van der Bruggen P, Van den Eynde BJ, Degiovanni G. A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. Int J Cancer. 1999 Dec 10, 83(6):755-9. (PMID: 10597191)
tyrosinase	melanoma	B35	20	TPRLPSSADVEF	309-320	autologous tumor cells	Benlalam, 2003	Benlalam H, Linard B, Guilloux Y, Moreau-Aubry A, Derré L, Diez E, Dreno B, Jotereau F, Labarrière N. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol. 2003 Dec 1, 171(11):6283-9. (PMID: 14634146)
tyrosinase	melanoma	B38	5	LHHAFVDSIF	388-397	autologous tumor cells	Lennerz, 2005	Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005 Nov 1, 102(44):16013-8. (PMID: 16247014)
tyrosinase	melanoma	DR4	24	QNILLSNAPLGPQFP	56-70	autologous tumor cells	Topalian, 1996	Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996 May 1, 183(5):1965-71. (PMID: 8642306)
tyrosinase	melanoma	DR4	24	SYLQDSDPDSFQD	450-462	autologous tumor cells	Topalian, 1996	Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med. 1996 May 1, 183(5):1965-71. (PMID: 8642306)
tyrosinase	melanoma	B44	21	SEIWRDIDFd	192-200	autologous tumor cells	Brichard, 1996	Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wölfel T, Boon T, Lethé B. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur J Immunol. 1996 Jan, 26(1):224-30. (PMID: 8566071)
tyrosinase	melanoma	DR15	20	FLLHHAFVDSIFEQWLQRHRP	386-406	autologous tumor cells	Kobayashi, 1998	Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M. CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. 1998 Jan 15, 58(2):296-301. (PMID: 9443408)

Gene/Protein ⓘ	Normal/Tumor ⓘ	HLA ⓘ	HLA% ⓘ	Peptide Sequence	Position ⓘ	Lymphocyte Stimulation ⓘ	Reference ⓘ	Full Reference	Note	Note ⓘ
AIM-2	ubiquitous (low level)	A1	26	RSDSGQQARY	intron	autologous tumor cells	Harada, 2001	Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. J Immunother. 2001 Jul-Aug, 24(4):323-33. (PMID: 11565834)
Meloe	ubiquitous (low level)	A2	44	TLNDECWPA	36-44	tumor-infiltrating lymphocytes	Godet, 2008	Godet Y, Moreau-Aubry A, Guilloux Y, Vignard V, Khammari A, Dreno B, Jotereau F, Labarriere N. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med. 2008 Oct 27, 205(11):2673-82. (PMID: 18936238)
Meloe	ubiquitous (low level)	DQ2	41	ERISSTLNDECWPA	31-44	peptide/protein	Bobinet, 2012	Bobinet M, Vignard V, Rogel A, Khammari A, Dreno B, Lang F, Labarriere N. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One. 2012, 7(12):e51716. (PMID: 23284752)
Meloe	ubiquitous (low level)	DQ6	63	FGRLQGISPKI	32-44	peptide	Rogel, 2011	Rogel A, Vignard V, Bobinet M, Labarriere N, Lang F. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother. 2011 Mar, 60(3):327-37. (PMID: 21080167)
Meloe	ubiquitous (low level)	DR1	18	TSREQFLPSEGAA	11-23	peptide/protein	Bobinet, 2012	Bobinet M, Vignard V, Rogel A, Khammari A, Dreno B, Lang F, Labarriere N. MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients. PLoS One. 2012, 7(12):e51716. (PMID: 23284752)
Meloe	ubiquitous (low level)	DR11	25	CPPWHPSERISSTL	24-37	peptide	Rogel, 2011	Rogel A, Vignard V, Bobinet M, Labarriere N, Lang F. A long peptide from MELOE-1 contains multiple HLA class II T cell epitopes in addition to the HLA-A*0201 epitope: an attractive candidate for melanoma vaccination. Cancer Immunol Immunother. 2011 Mar, 60(3):327-37. (PMID: 21080167)
MUC5AC	surface mucosal cells, respiratory tract, and stomach epithelia	A24	20	TCQPTCRSL	716-724	peptide	Yamazoe, 2011	Yamazoe S, Tanaka H, Iwauchi T, Yoshii M, Ito G, Amano R, Yamada N, Sawada T, Ohira M, Hirakawa K. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Pancreas. 2011 Aug, 40(6):896-904. (PMID: 21697763)
RAGE-1	retina	A2	44	LKLSGVVRL	352-360	peptide	Oehlrich, 2005	Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605)
RAGE-1	retina	A2	44	PLPPARNGGLg	32-40	peptide	Oehlrich, 2005	Oehlrich N, Devitt G, Linnebacher M, Schwitalle Y, Grosskinski S, Stevanovic S, Zöller M. Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer. 2005 Nov 1, 117(2):256-64. (PMID: 15900605)
RAGE-1	retina	B7	17	SPSSNRIRNT	11-20	autologous tumor cells	Gaugler, 1996	Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 1996, 44(5):323-30. (PMID: 8781117)
RNF43		A2	44	ALWPWLLMA(T)	11-19(20)	peptide	Uchida, 2004	Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15, 10(24):8577-86. (PMID: 15623641)
RNF43		A24	20	NSQPVWLCL	721-729	peptide	Uchida, 2004	Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15, 10(24):8577-86. (PMID: 15623641)
HSPH1	ubiquitous (low level)	A24	20	NYGIYKQDL	180-188	peptide	Shimizu, 2019	Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Sci 2019, 110: 3049-3060. (PMID: 31390678)
HSPH1	ubiquitous (low level)	A2	44	RLMNDMTAV	169-177	peptide	Shimizu, 2019	Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer Sci 2019, 110: 3049-3060. (PMID: 31390678)
adipophilin	adipocytes, macrophages	A2	44	SVASTITGV	129-137	peptide	Schmidt, 2004	Schmidt SM, Schag K, Müller MR, Weinschenk T, Appel S, Schoor O, Weck MM, Grünebach F, Kanz L, Stevanovic S, Rammensee HG, Brossart P. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 2004 Feb 1, 64(3):1164-70. (PMID: 14871853)
BCLX (L)	ubiquitous (low level)	A2	44	YLNDHLEPWI	173-182	peptide	Sørensen, 2007	Sørensen RB1, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother. 2007 Apr, 56(4):527-33. (PMID: 16850344)
BING-4	ubiquitous (low level)	A2	44	CQWGRLWQL	ORF2	anti-CD3	Rosenberg, 2002	Rosenberg SA, Tong-On P, Li Y, Riley JP, El-Gamil M, Parkhurst MR, Robbins PF. Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J Immunol. 2002 Mar 1, 168(5):2402-7. (PMID: 11859131)
CALCA	thyroid	A2	44	VLLQAGSLHA	16-25	autologous tumor cells	El Hage, 2008	El Hage F, Stroobant V, Vergnon I, Baurain JF, Echchakir H, Lazar V, Chouaib S, Coulie PG, Mami-Chouaib F. Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A. 2008 Jul 22, 105(29):10119-24. (PMID: 18626012)
ALDH1A1	mucosa, keratinocytes	A2	44	LLYKLADLI	88-96	peptide	Visus, 2007	Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007 Nov 1, 67(21):10538-45. (PMID: 17974998)
cyclin D1	ubiquitous (low level)	DR4	24	NPPSMVAAGSVVAAV	198-212	peptide	Dengjel, 2004	Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, Rammensee HG, Stevanovic S. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol. 2004 Dec, 34(12):3644-51. (PMID: 15495271)
DKK1	testis, prostate,	A2	44	ALGGHPLLGV	20-29	peptide	Qian, 2007	Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 1, 110(5):1587-94. (PMID: 17515399)
DKK1	mesenchymal stem cells	A2	44	ALGGHPLLGV	20-30	peptide	Qian, 2007	Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 1, 110(5):1587-94. (PMID: 17515399)
ENAH (hMena)	breast, prostate stroma and epithelium of colon-rectum, pancreas, endometrium	A2	44	TMNGSKSPV	502-510	peptide	Di Modugno, 2004	Di Modugno F, Bronzi G, Scanlan MJ, Del Bello D, Cascioli S, Venturo I, Botti C, Nicotra MR, Mottolese M, Natali PG, Santoni A, Jager E, Nisticò P. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer. 2004 May 10, 109(6):909-18. (PMID: 15027125)
EpCAM	epithelial cells	A24	20	RYQLDPKFI	173-181	peptide	Tajima, 2004	Tajima K, Demachi A, Ito Y, Nishida K, Akatsuka Y, Tsujimura K, Kuwano H, Mitsudomi T, Takahashi T, Kuzushima K. Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses. Tissue Antigens. 2004 Dec, 64(6):650-9. (PMID: 15546337)
EphA3	many	DR11	25	DVTFNIICKKCG	356-367	autologous tumor cells	Chiari, 2000	Chiari R, Hames G, Stroobant V, Texier C, Maillère B, Boon T, Coulie PG. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res. 2000 Sep 1, 60(17):4855-63. (PMID: 10987298)
EZH2	ubiquitous (low level)	A2	44	FMVEDETVL	120-128	peptide	Itoh, 2007	Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov, 18(5):1231-7. (PMID: 17914578)
EZH2	ubiquitous (low level)	A24	20	KYDCFLHPF	291-299	peptide	Ogata, 2004	Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate. 2004 Sep 1, 60(4):273-81. (PMID: 15264237)
EZH2	ubiquitous (low level)	A2	44	FINDEIFVEL	165-174	peptide	Itoh, 2007	Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov, 18(5):1231-7. (PMID: 17914578)
EZH2	ubiquitous (low level)	A24	20	KYVGIEREM	735-743	peptide	Ogata, 2004	Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate. 2004 Sep 1, 60(4):273-81. (PMID: 15264237)
FGF5	brain, kidney	A3	22	NTYASPRFKf	172-176 and 217-220	autologous tumor cells	Hanada, 2004	Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004 Jan 15, 427(6971):252-6. (PMID: 14724640)
glypican-3	placental and multiple tissues	A2	44	FVGEFFTDV	144-152	peptide	Komori, 2006	Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1, 12(9):2689-97. (PMID: 16675560)
glypican-3	placental and multiple tissues	A24	20	EYILSLEEL	298-306	peptide	Komori, 2006	Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006 May 1, 12(9):2689-97. (PMID: 16675560)
CPSF	ubiquitous (low level)	A2	44	LMLQNALTTM	1360-1369	autologous tumor cells	Maeda, 2002	Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer. 2002 May 20, 99(3):409-17. (PMID: 11992410)
CD274	multiple tissues (lung, heart, dendritic cells,?) and induced by IFN-?	A2	44	LLNAFTVTV	15-23	peptide	Munir, 2012	Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 2013 Mar 15, 73(6):1764-76. (PMID: 23328583)
HER-2 / neu	ubiquitous (low level)	A2	44	KIFGSLAFL	369-377	autologous tumor cells	Fisk, 1995	Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995 Jun 1, 181(6):2109-17. (PMID: 7539040)
HER-2 / neu	ubiquitous (low level)	A2	44	IISAVVGIL	654-662	peptide	Brossart, 1998	Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998 Feb 15, 58(4):732-6. (PMID: 9485028)
HER-2 / neu	ubiquitous (low level)	A2	44	ALCRWGLLL	13-May	peptide	Kawashima, 1998	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234)
CD45	proliferating cells, testis, multiple tissues (low level)	A24	20	KFLDALISL	556-564	peptide	Tomita, 2011	Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T, Ito T, Nomori H, Nakamura Y, Kohrogi H, Nishimura Y. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr, 102(4):697-705. (PMID: 21231984)
cyclin D1	ubiquitous (low level)	A2	44	LLGATCMFV	101-109	peptide	Kondo, 2008	Kondo E, Maecker B, Weihrauch MR, Wickenhauser C, Zeng W, Nadler LM, Schultze JL, von Bergwelt-Baildon MS. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res. 2008 Oct 15, 14(20):6574-9. (PMID: 18927298)
CPSF	ubiquitous (low level)	A2	44	KVHPVIWSL	250-258	autologous tumor cells	Maeda, 2002	Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer. 2002 May 20, 99(3):409-17. (PMID: 11992410)
G250 / MN / CAIX	stomach, liver, pancreas	A2	44	HLSTAFARV	254-262	peptide	Vissers, 1999	Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999 Nov 1, 59(21):5554-9. (PMID: 10554034)
HER-2 / neu	ubiquitous (low level)	A2	44	ILHNGAYSL	435-443	peptide	Kawashima, 1998	Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998 Jan, 59(1):1-14. (PMID: 9544234)
HER-2 / neu	ubiquitous (low level)	A2	44	VVLGVVFGI	665-673	peptide	Rongcun, 1999	Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702)
HER-2 / neu	ubiquitous (low level)	A2	44	YMIMVKCWMI	952-961	peptide	Rongcun, 1999	Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702)
HER-2 / neu	ubiquitous (low level)	A2	44	YLVPQQGFFC	1023-1032	peptide	Scardino, 2001	Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol. 2001 Nov, 31(11):3261-70. (PMID: 11745343)
HER-2 / neu	ubiquitous (low level)	A2	44	RLLQETELV	689-697	peptide	Rongcun, 1999	Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol. 1999 Jul 15, 163(2):1037-44. (PMID: 10395702)
HER-2 / neu	ubiquitous (low level)	A2	44	HLYQGCQVV	48-56	peptide	Scardino, 2001	Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol. 2001 Nov, 31(11):3261-70. (PMID: 11745343)
HER-2 / neu	ubiquitous (low level)	A2	44	PLQPEQLQV	391-399	peptided	Scardino, 2002	Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395)
HER-2 / neu	ubiquitous (low level)	A2	44	ALIHHNTHL	466-474	peptided	Scardino, 2002	Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395)
HER-2 / neu	ubiquitous (low level)	A2	44	TLEEITGYL	402-410	peptided	Scardino, 2002	Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395)
HER-2 / neu	ubiquitous (low level)	A3	22	VLRENTSPK	754-762	peptide	Kawashima, 1999	Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 1999 Jan 15, 59(2):431-5. (PMID: 9927058)
HER-2 / neu	ubiquitous (low level)	A24	20	TYLPTNASL	63-71	peptide	Okugawa, 2000	Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol. 2000 Nov, 30(11):3338-46. (PMID: 11093150)
HLA-DOB	B lymphocytes, monocytes, blood cells, adrenals, ?	A2	44	FLLGLIFLL	232-240	peptide	Kang, 2013	Kang YJ, Zeng W, Song W, Reinhold B, Choi J, Brusic V, Yamashita T, Munshi A, Li C, Minvielle S, Anderson KC, Munshi N, Reinherz EL, Sasada T. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma. Br J Haematol. 2013 Nov, 163(3):343-51. (PMID: 24032635)
Hepsin	kidney, liver, skin, ?	A2	44	SLLSGDWVL	191-199	peptide	Guo, 2013	Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092)
Hepsin	kidney, liver, skin, ?	A2	44	GLQLGVQAV	229-237	peptide	Guo, 2013	Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092)
Hepsin	kidney, liver, skin, ?	A2	44	PLTEYIQPV	268-276	peptide	Guo, 2013	Guo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XH. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy. Scand J Immunol. 2013 Sep, 78(3):248-57. (PMID: 23721092)
IGF2B3	ubiquitous (low level)	A2	44	NLSSAEVVV	515-523	peptide	Tomita, 2011	Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci. 2011 Jan, 102(1):71-8. (PMID: 21087352)
IL13Ralpha2		A2	44	WLPFGFILI	345-353	peptide	Okano, 2002	Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002 Sep, 8(9):2851-5. (PMID: 12231526)
IGF2B3	ubiquitous (low level)	A3	44	RLLVPTQFV	199-207	peptide	Tomita, 2011	Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K, Mori T, Nomori H, Kohrogi H, Nishimura Y. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci. 2011 Jan, 102(1):71-8. (PMID: 21087352)
Intestinal carboxyl esterase	liver, intestine, kidney	B7	17	SPRWWPTCL	alt. ORF	autologous tumor cells	Ronsin, 1999	Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol. 1999 Jul 1, 163(1):483-90. (PMID: 10384152)
HER-2 / neu	ubiquitous (low level)	A2	44	PLTSIISAV	650-658	peptided	Scardino, 2002	Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 2002 Jun 1, 168(11):5900-6. (PMID: 12023395)
alpha-foetoprotein (AFP)	liver	A2	44	GVALQTMKQ	542-550	adenovirus-dendritic cells	Butterfield, 1999	Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999 Jul 1, 59(13):3134-42. (PMID: 10397256)
alpha-foetoprotein (AFP)	liver	DR13	19	QLAVSVILRV	364-373	peptide	Alisa, 2005	Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, Behboudi S. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 2005 Sep 15, 11(18):6686-94. (PMID: 16166448)
alpha-foetoprotein (AFP)	liver	A2	44	FMNKFIYEI	158-166	peptide	Pichard, 2008	Pichard V, Royer PJ, Richou C, Cauchin E, Goebes K, Gaignerie A, Masliah C, Gournay J, Gregoire M, Ferry N. Detection, isolation, and characterization of alpha-fetoprotein-specific T cell populations and clones using MHC class I multimer magnetic sorting. J Immunother. 2008 Apr, 31(3):246-53. (PMID: 18317363)
Kallikrein 4	prostate and ovarian cancer cancer	A2	44	FLGYLILGV	11-19	peptide	Wilkinson, 2012	Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, Hardy MY, Dong Y, Clements JA, Hart DN, Radford KJ. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother. 2012 Feb, 61(2):169-79. (PMID: 21874303)
Kallikrein 4	prostate and ovarian cancer cancer	DR4	24	LLANGRMPTVLQCVN	155-169	peptide	Hural, 2002	Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288)
Kallikrein 4	prostate and ovarian cancer cancer	DP4	75	SVSESDTIRSISIAS	125-139	peptide	Hural, 2002	Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288)
KIF20A	ubiquitous (low level)	A2	44	AQPDTAPLPV	284-293	peptide	Imai, 2011	Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034)
Kallikrein 4	prostate and ovarian cancer cancer	DR7	25	RMPTVLQCVNVSVVS	160-174	peptide	Hural, 2002	Hural JA, Friedman RS, McNabb A, Steen SS, Henderson RA, Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J Immunol. 2002 Jul 1, 169(1):557-65. (PMID: 12077288)
KIF20A	ubiquitous (low level)	A2	44	LLSDDDVVV	12-20	peptide	Imai, 2011	Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034)
KIF20A	ubiquitous (low level)	A2	44	CIAEQYHTV	809-817	peptide	Imai, 2011	Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011 Jan 1, 104(2):300-7. (PMID: 21179034)
Lengsin	eye lens and low level in multiple tissues	A2	44	FLPEFGISSA	270-279	peptide	Nakatsugawa, 2011	Nakatsugawa M, Horie K, Yoshikawa T, Shimomura M, Kikuchi Y, Sakemura N, Suzuki S, Nobuoka D, Hirohashi Y, Torigoe T, Harada K, Takasu H, Sato N, Nakatsura T. Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin. Int J Oncol. 2011 Oct, 39(4):1041-9. (PMID: 21687943)
MCSP	endothelial cells, chondrocytes, smooth muscle cells	DR11	25	VGQDVSVLFRVTGALQ	693-708	peptide	Erfurt, 2007	Erfurt C, Sun Z, Haendle I, Schuler-Thurner B, Heirman C, Thielemans K, van der Bruggen P, Schuler G, Schultz ES. Tumor-reactive CD4+ T cell responses to the melanoma-associated chondroitin sulphate proteoglycan in melanoma patients and healthy individuals in the absence of autoimmunity. J Immunol. 2007 Jun 15, 178(12):7703-9. (PMID: 17548607)
M-CSF	liver, kidney	B35	20	LPAVVGLSPGEQEY	alt. ORF	autologous tumor cells	Probst-Kepper, 2001	Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van Den Eynde BJ. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med. 2001 May 21, 193(10):1189-98. (PMID: 11369790)
mdm-2	ubiquitous (brain, muscle, lung)	A2	44	VLFYLGQY	53-60	tumor lysate-pulsed APCs	Asai, 2002	Asai T, Storkus W, Mueller-Berghaus J, Knapp W, DeLeo A, Chikamatsu K, Whiteside T. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. 2002 January.
IDO1	lymph nodes, placenta, and many cell types in the course of inflammatory response	A2	44	ALLEIASCL	199-207	peptide	Sørensen, 2009	Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One. 2009 Sep 7, 4(9):e6910. (PMID: 19738905 )
Midkine	ubiquitous (low level)	A2	44	ALLALTSAV	13-21	peptide	Kerzerho, 2010	Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010 Jul 1, 185(1):418-23. (PMID: 20511550)
MMP-2	ubiquitous	A2	44	GLPPDVQRVh	560-568	autologous tumor cells	Godefroy, 2005	Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005 Jul 4, 202(1):61-72. (PMID: 15998788)
MMP-7	ubiquitous (low level)	A3	22	SLFPNSPKWTSK	96-107	peptide	Yokoyama, 2008	Yokoyama Y, Grünebach F, Schmidt SM, Heine A, Häntschel M, Stevanovic S, Rammensee HG, Brossart P. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res. 2008 Sep 1, 14(17):5503-11. (PMID: 18765542)
Midkine	ubiquitous (low level)	DR4	24	LTLLALLALTSAVAK	9-23	peptide	Kerzerho, 2013	Kerzerho J, Schneider A, Favry E, Castelli FA, Maillère B. The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes. J Biol Chem. 2013 May 10, 288(19):13370-7. (PMID: 23553629)
MUC1	glandular epithelia	A2	44	STAPPVHNV	950-958	peptide	Brossart, 1999	Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999 Jun 15, 93(12):4309-17. (PMID: 10361129)
MUC1	glandular epithelia	A2	44	LLLLTVLTV	12-20	peptide	Brossart, 1999	Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999 Jun 15, 93(12):4309-17. (PMID: 10361129)
MUC1	glandular epithelia	DR3	21	PGSTAPPAHGVT	repeated region	peptide	Hiltbold, 1998	Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 1998 Nov 15, 58(22):5066-70. (PMID: 9823312)
PAX5	hemopoietic system	A2	44	TLPGYPPHV	311-319	peptide	Yan, 2008	Yan M, Himoudi N, Pule M, Sebire N, Poon E, Blair A, Williams O, Anderson J. Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy. Cancer Res. 2008 Oct 1, 68(19):8058-65. (PMID: 1882956)
p53	ubiquitous (low level)	B46	0	SQKTYQGSY	99-107	autologous tumor cells	Azuma, 2003	Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, Koike K, Itoh K. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 2003 Feb 15, 63(4):854-8. (PMID: 12591737)
p53	ubiquitous (low level)	DP5	3	PGTRVRAMAIYKQ	153-165	peptide	Fujita, 1998	Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol. 1998 Jan, 28(1):305-16. (PMID: 9485210)
p53	ubiquitous (low level)	A2	44	RMPEAAPPV	65-73	peptide	Barfoed, 2000	Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000 Feb, 51(2):128-33. (PMID: 10652158)
PBF	ovary, pancreas, spleen, liver	B55	4	CTACRWKKACQR	499-510	autologous tumor cells	Tsukahara, 2004	Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T, Sato N. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004 Aug 1, 64(15):5442-8. (PMID: 15289353)
PRAME	testis, ovary, endometrium, adrenals	A2	44	VLDGLDVLL	100-108	peptide	Kessler, 2001	Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822)
PRAME	testis, ovary, endometrium, adrenals	A2	44	ALYVDSLFFL	300-309	peptide	Kessler, 2001	Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822)
PRAME	testis, ovary, endometrium, adrenals	A2	44	SLYSFPEPEA	142-151	peptide	Kessler, 2001	Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822)
PRAME	testis, ovary, endometrium, adrenals	A2	44	SLLQHLIGL	425-433	peptide	Kessler, 2001	Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, Offringa R, Melief CJ. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 2001 Jan 1, 193(1):73-88. (PMID: 11136822)
PSMA	prostate, CNS, liver	A24	20	NYARTEDFF	178-186	peptide	Horiguchi, 2002	Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002 Dec, 8(12):3885-92. (PMID: 12473604)
PRAME	testis, ovary, endometrium, adrenals	A24	20	LYVDSLFFLc	301-309	autologous tumor cells	Ikeda, 1997	Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997 Feb, 6(2):199-208. (PMID: 9047241)
RGS5	heart, skeletal muscle, pericytes	A3	22	GLASFKSFLK	74-83	peptide	Boss, 2007	Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 2007 Jun 1, 13(11):3347-55. (PMID: 17545542)
RGS5	heart, skeletal muscle, pericytes	A2	44	LAALPHSCL	5-13	peptide	Boss, 2007	Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG, Brossart P. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 2007 Jun 1, 13(11):3347-55. (PMID: 17545542)
p53	ubiquitous (low level)	DR14	6	HLIRVEGNLRVE	193-204	peptide	Fujita, 1998	Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol. 1998 Jan, 28(1):305-16. (PMID: 9485210)
RhoC	ubiquitous (low level)	A3	22	RAGLQVRKNK	176-185	peptide	Wenandy, 2008	Wenandy L, Sørensen RB, Svane IM, Thor Straten P, Andersen MH. RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol Immunother. 2008 Dec, 57(12):1871-8. (PMID: 18415097)
p53	ubiquitous (low level)	A2	44	LLGRNSFEV	264-272	peptide	Röpke, 1996	Röpke M, Hald J, Guldberg P, Zeuthen J, Nørgaard L, Fugger L, Svejgaard A, Van der Burg S, Nijman HW, Melief CJ, Claesson MH. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A. 1996 Dec 10, 93(25):14704-7. (PMID: 8962118)
RU2AS	testis, kidney, bladder	B7	17	LPRWPPPQL	antisense	autologous tumor cells	Van Den Eynde, 1999	Van Den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med. 1999 Dec 20, 190(12):1793-800. (PMID: 10601354)
secernin 1	ubiquitous	A2	44	KMDAEHPEL	196-204	peptide	Suda, 2006	Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May, 97(5):411-9. (PMID: 16630140)
Midkine	ubiquitous (low level)	A2	44	AQCQETIRV	114-122	peptide	Kerzerho, 2010	Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B. The angiogenic growth factor and biomarker midkine is a tumor-shared antigen. J Immunol. 2010 Jul 1, 185(1):418-23. (PMID: 20511550)
SOX10	ubiquitous (low level)	A2	44	AWISKPPGV	332-340	tumor-infiltrating lymphocytes	Khong, 2002	Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun 1, 62(11):3020-3. (PMID: 12036907)
SOX10	ubiquitous (low level)	A2	44	SAWISKPPGV	331-340	tumor-infiltrating lymphocytes	Khong, 2002	Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun 1, 62(11):3020-3. (PMID: 12036907)
STEAP1	prostate	A2	44	MIAVFLPIV	292-300	peptide	Rodeberg, 2005	Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res. 2005 Jun 15, 11(12):4545-52. (PMID: 15958640)
STEAP1	prostate	A2	44	HQQYFYKIPILVINK	102-116	peptide	Kobayashi, 2007	Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res. 2007 Jun 1, 67(11):5498-504. (PMID: 17545632)
survivin	ubiquitous	A2	44	ELTLGEFLKL	95-104	peptide / protein	Schmitz, 2000	Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000 Sep 1, 60(17):4845-9. (PMID: 10987296)
Telomerase	testis, thymus, bone marrow, lymph nodes	A2	44	ILAKFLHWLe	540-548	peptide	Vonderheide, 1999	Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999 Jun, 10(6):673-9. (PMID: 10403642)
Telomerase	testis, thymus, bone marrow, lymph nodes	DR7	25	RPGLLGASVLGLDDI	672-686	peptide	Schroers, 2002	Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002 May 1, 62(9):2600-5. (PMID: 11980655)
Telomerase	testis, thymus, bone marrow, lymph nodes	A2	44	RLVDDFLLV	865-873	peptide	Minev, 2000	Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000 Apr 25, 97(9):4796-801. (PMID: 10759561)
WT1	testis, ovary, bone marrow, spleen	A1	26	TSEKRPFMCAY	317-327	peptide	Asemissen, 2006	Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res. 2006 Dec 15, 12(24):7476-82. (PMID: 17189421)
WT1	testis, ovary, bone marrow, spleen	A24	20	CMTWNQMNL	235-243	peptide	Ohminami, 2000	Ohminami H1, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000 Jan 1, 95(1):286-93. (PMID: 10607714)
survivin	ubiquitous	A2	44	ELTLGEFLKL	95-104	peptide / protein	Schmidt, 2003	Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003 Jul 15, 102(2):571-6. (PMID: 12576330)
TPBG	multiple tissues (esophagus, bladder, ?)	A2	44	RLARLALVL	17-25	peptide	Tykodi, 2012	Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH. CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. J Immunother. 2012 Sep, 35(7):523-33. (PMID: 22892449)
WT1	testis, ovary, bone marrow, spleen	DP5	3	KRYFKLSHLQMHSRKH	332-347	peptide	Lin, 2013	Lin Y, Fujiki F, Katsuhara A, Oka Y, Tsuboi A, Aoyama N, Tanii S, Nakajima H, Tatsumi N, Morimoto S, Tamanaka T, Tachino S, Hosen N, Nishida S, Oji Y, Kumanogoh A, Sugiyama H. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. J Immunother. 2013 Apr, 36(3):159-70. (PMID: 23502763)
WT1	testis, ovary, bone marrow, spleen	DR4	24	KRYFKLSHLQMHSRKH	332-347	peptide	Fujiki, 2007	Fujiki F1, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother. 2007 Apr, 30(3):282-93. (PMID: 17414319)
VEGF	ubiquitous (low level)	B27	7	SRFGGAVVR	-i	peptide	Weinzierl, 2008	Weinzierl AO1, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, Wernet D, Joos T, Rammensee HG, Stevanović S. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 2008 Apr 1, 68(7):2447-54. (PMID: 18381453)
WT1	testis, ovary, bone marrow, spleen	DP5	3	LSHLQMHSRKH	337-347	peptide	Guo, 2005	Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, Yasukawa M. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood. 2005 Aug 15, 106(4):1415-8. (PMID: 15845894)
Telomerase	testis, thymus, bone marrow, lymph nodes	DR11	25	LTDLQPYMRQFVAHL	766-780	peptide	Schroers, 2003	Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003 Oct 15, 9(13):4743-55. (PMID: 14581345)
survivin	ubiquitous	DR1	18	TLGEFLKLDRERAKN	97-111	peptide / protein	Widenmeyer, 2012	Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2012 Jul 1, 131(1):140-9. (PMID: 21858810)
glypican-3	placental and multiple tissues	A2	44	TIHDSIQYV	325-334	mRNA-transfected cells	Dargel, 2015	Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Gastroenterology. 2015, 149(4): 1042-52. (PMID: 26052074)
nectin-4	placental tissues and salivary gland	A2	44	VLVPPLPSL	145-153	peptide	Lopez, 2016	Lopez M, Ghidouche A, Rochas C, Godelaine D, Carrasco J, Colau D, Hames G, Montero-Julian FA, Coulie PG, Olive D. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4. Cancer Immunol Immunother. 2016, 65(10): 1177-88. (PMID: 27514672)
IMP-3	ubiquitous (low level)	DR53	49	QSETETVHLFIPALSVGAIIGK	402-423	peptide	Hirayama, 2016	Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 2016, 5(6) :e1123368. (PMID: 27471607)
IMP-3	ubiquitous (low level)	DR9	3	GKTVNELQNLSSAEVVVPRDQ	507-527	peptide	Hirayama, 2016	Hirayama M, Tomita Y, Yuno A, Tsukamoto H, Senju S, Imamura Y, Sayem MA, Irie A, Yoshitake Y, Fukuma D, Shinohara M, Hamada A, Jono H, Yuba E, Kono K, Yoshida K, Tsunoda T, Nakayama H, Nishimura Y. An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs. Oncoimmunology. 2016, 5(6) :e1123368. (PMID: 27471607)
PLAC1	testis, skeletal muscle, lung	A2	44	VLCSIDWFM	28-36	peptide	Li, 2018	Li Q, Liu M, Wu M, Zhou X, Wang S, Hu Y, Wang Y, He Y, Zeng X, Chen J, Liu Q, Xiao D, Hu X, Liu W. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer. Oncol Lett. 2018, 15(4): 5924-5932. (PMID: 29556312)
HLA-G	lung, pituitary, multiple tissues (low level)	DR53	49	SHSMRYFSAAVSRPG	26-40	peptide	Ishibashi, 2016	Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology. 2016, 5(6): e1169356. (PMID: 7471649)
HLA-G	lung, pituitary, multiple tissues (low level)	DR15	20	SHSMRYFSAAVSRPG	26-40	peptide	Ishibashi, 2016	Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. Oncoimmunology. 2016, 5(6): e1169356. (PMID: 7471649)
CALCA	thyroid	A2	44	FLALSILVL	9-17	peptide	Durgeau, 2018	Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837)
CALCA	thyroid	A2	44	LLAALVQDYL	50-59	peptide	Durgeau, 2018	Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837)
CALCA	thyroid	A2	44	CMLGTYTQDF	91-100	peptide	Durgeau, 2018	Durgeau A, Virk Y, Gros G, Voilin E, Corgnac S, Djenidi F, Salmon J, Adam J, de Montpréville V, Validire P, Ferrone S, Chouaib S, Eggermont A, Soria JC, Lemonnier F, Tartour E, Chaput N, Besse B, Mami-Chouaib F. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. at Commun. 2018 Nov 30, 9(1):5097. (PMID: 30504837)
HEPACAM		A2	44	RLAPFVYLL	16-24	peptide	Neidert, 2018	Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol. 2018 Jun, 135(6):923-938. (PMID: 29557506)
Telomerase	testis, thymus, bone marrow, lymph nodes	DP4	75	EARPALLTSRLRFIPK	611-626	peptide	Bernhardt, 2006	Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006; 95(11):1474-82. (PMCID: PMC2360729)

Reference ⓘ	comment	Note ⓘ
Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res 2010, 16: 4607-15. (PMID: 20670945)
Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006, 55: 1515-23. (PMID: 16622681)	undefined
Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002, 116: 601-3. (PMID: 11849218)	undefined
Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients. Clin Cancer Res 2004, 10: 6695-702. (PMID: 15475460)	undefined
Babiak A, Steinhauser M, Gotz M, Herbst C, Dohner H, Greiner J. 2014. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy. Oncol Rep 31: 384-90. (PMID: 24154794)
Bae J, Prabhala R, Voskertchian A, Brown A, Maguire C, Richardson P, Dranoff G, Anderson KC, Munshi NC. 2015. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29: 218-29. (PMID: 24935722)
Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee AH, Dranoff G, Anderson KC, Munshi NC. 2014. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology 3: e970914. (PMID: 25941601)
Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, Munshi NC. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol 2012, 157: 687-701. (PMID: 22533610)	undefined
Bar-Haim E, Paz A, Machlenkin A, Hazzan D, Tirosh B, Carmon L, Brenner B, Vadai E, Mor O, Stein A, Lemonnier FA, Tzehoval E, Eisenbach L. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br J Cancer 2004, 91: 398-407. (PMID: 15213716)	undefined
Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J, Swoboda R, Strittmatter W, Li W, Luckenbach A, Song H, Li J, Sproesser K, Guerry D, Nair S, Furukawa K, Herlyn D. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003, 52: 145-54. (PMID: 12649743)	undefined
Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002, 100: 3835-7. (PMID: 12411326)	undefined
Akiyama Y, Komiyama M, Nakamura Y, Iizuka A, Oshita C, Kume A, Nogami M, Miyata H, Ashizawa T, Yoshikawa S, Kiyohara Y, Yamaguchi K. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay. Cancer Immunol. Immunother. 2012, 61: 2311-9. (PMID: 22707303)
Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 2003, 63: 8476-80. (PMID: 14679012)	undefined
Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG. Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 2000, 49: 459-68. (PMID: 11092612)	undefined
Alisa A, Boswell S, Pathan AA, Ayaru L, Williams R, Behboudi S. Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4(+) T cells. J Immunol 2008, 180: 5109-17. (PMID: 18354237)	undefined
Belle S, Han F, Condomines M, Christensen O, Witzens-Harig M, Kasper B, Kleist C, Terness P, Moos M, Cremer F, Hose D, Ho AD, Goldschmidt H, Klein B, Hundemer M. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma. Eur J Haematol 2008, 81: 26-35. (PMID: 18363871)	undefined
Bohm CM, Hanski ML, Stefanovic S, Rammensee HG, Stein H, Taylor-Papadimitriou J, Riecken EO, Hanski C. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int J Cancer 1998, 75: 688-93. (PMID: 9495235)	undefined
Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005, 174: 1709-16. (PMID: 15661935)	undefined
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol 2007, 35: 920-30. (PMID: 17533046)	undefined
Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001, 166: 5300-8. (PMID: 11290817)	undefined
Buzyn A, Ostankovitch M, Zerbib A, Kemula M, Connan F, Varet B, Guillet JG, Choppin J. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997, 27: 2066-72. (PMID: 9295046)	undefined
Carlsson B, Totterman TH, Essand M. 2004. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 61: 161-70. (PMID: 15305339)
Carmon L, Bobilev-Priel I, Brenner B, Bobilev D, Paz A, Bar-Haim E, Tirosh B, Klein T, Fridkin M, Lemonnier F, Tzehoval E, Eisenbach L. Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J Clin Invest 2002, 110: 453-62. (PMID: 12189239)	undefined
Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 2008, 10: 977-86. (PMID: 18714399)	undefined
Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother 2011, 60: 23-35. (PMID: 20857101)
Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Br”cker EB, thor Straten P, Rapp UR, Becker JC. Immunogenicity of constitutively active V599EBRaf. Cancer Res 2004, 64: 5456-60. (PMID: 15289355)	undefined
Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB. P53110-124-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003, 63: 3675-81. (PMID: 12839958)	undefined
Chevaleyre C, Benhamouda N, Favry E, Fabre E, Mhoumadi A, Nozach H, Marcon E, Cosler G, Vinatier E, Oudard S, Hans S, Le Pimpec-Barthes F, Bats AS, Castelli FA, Tartour E, Maillere B. 2015. The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. J Immunol 2015, 195: 1891-901. (PMID: 26136431)
Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanovic S, Stickel JS. 2015. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 29: 647-59. (PMID: 25092142)
Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001, 98: 2887-93. (PMID: 11698267)	undefined
Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87: 3587-92. (PMID: 8611681)	undefined
Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol 2007, 178: 1914-22. (PMID: 17237442)	undefined
Coleman JA, Correa I, Cooper L, Bohnenkamp HR, Poulsom R, Burchell JM, Taylor-Papadimitriou J. T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients. Int J Cancer 2011, 128: 2114-24. (PMID: 21105039)
Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998, 114: 166-72. (PMID: 9822272)	undefined
Correa I, Plunkett T, Coleman J, Galani E, Windmill E, Burchell JM, Taylor-Papdimitriou J. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005, 115: 760-8. (PMID: 15729696)	undefined
Dangles V, Halberstam I, Scardino A, Choppin J, Wertheimer M, Richon S, Quelvennec E, Moirand R, Guillet JG, Kosmatopoulos K, Bellet D, Zeliszewski D. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes. Cancer Immunol Immunother 2002, 50: 673-81. (PMID: 11862419)	undefined
Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scott AM, Maraskovsky E, McArthur G, MacGregor D, Sturrock S, Tai TY, Green S, Cuthbertson A, Maher D, Miloradovic L, Mitchell SV, Ritter G, Jungbluth AA, Chen YT, Gnjatic S, Hoffman EW, Old LJ, Cebon JS. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 2004, 101: 10697-702. (PMID: 15252201)	undefined
Dörrschuck A, Schmidt A, Schnürer E, Glückmann M, Albrecht C, Wölfel C, Lennerz V, Lifke A, Di Natale C, Ranieri E, Gesualdo L, Huber C, Karas M, W”lfel T, Herr W. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 2004, 104: 2591-9. (PMID: 15231579)
Duan ZL, Wang ZB, Guo JL, Liu WQ, Hu J, Li J, Wang SN, Li Q, Wen JS. Two novel squamous cell carcinoma antigen-derived HLA-A*0201-binding peptides induce in vitro and in vivo CD8+ cytotoxic T lymphocyte responses. Int. J. Oncol. 2013, 42: 1482-92. (PMID: 23426430)
Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Am J Obstet Gynecol 2009, 200: 75.e1-10. (PMID: 18976739)
Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol Immunother 2008, 57: 833-47. (PMID: 18004564)	undefined
Elkord E, Williams PE, Kynaston H, Rowbottom AW. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Int Immunol 2005, 17: 1315-25. (PMID: 16141246)	undefined
Erfurt C, Muller E, Emmerling S, Klotz C, Hertl M, Schuler G, Schultz ES. Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients. Int J Cancer 2009, 124: 2341-6. (PMID: 19173283)	undefined
Dermime S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, Pogliani E, Parmiani G, Gambacorti-Passerini C. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996, 2: 593-600. (PMID: 9816208)
Flad T, Mueller L, Dihazi H, Grigorova V, Bogumil R, Beck A, Thedieck C, Mueller GA, Kalbacher H, Mueller CA. T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics 2006, 6: 364-74. (PMID: 16196104)	undefined
Faure O, Graff-Dubois S, Bretaudeau L, Derr‚ L, Gross D-A, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gr‚goire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K. Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 2004, 108: 863-70. (PMID: 14712489)	undefined
Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro. Cancer Lett 2004, 211: 219-25. (PMID: 15219945)	undefined
Fleischhauer K, Gattinoni L, Dalerba P, Lauvau G, Zanaria E, Dabovic B, van Endert PM, Bordignon C, Traversari C. The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes. Cancer Res 1998, 58: 2969-72. (PMID: 9679956)	undefined
Friedman RS, Spies AG, Kalos M. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol 2004b, 34: 1091-101. (PMID: 15048720)	undefined
Francini G, Scardino A, Kosmatopoulos K, Lemonnier FA, Campoccia G, Sabatino M, Pozzessere D, Petrioli R, Lozzi L, Neri P, Fanetti G, Cusi MG, Correale P. High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J Immunol 2002, 169: 4840-9. (PMID: 12391194)	undefined
Forget MA, Reuben A, Turcotte S, Martin J, Lapointe R. Polyfunctionality of a DKK1 self-antigen-specific CD8(+) T lymphocyte clone in lung cancer. Cancer Immunol Immunother 2011, 60: 1119-25. (PMID: 21681374)
Friedman RS, Bangur CS, Zasloff EJ, Fan L, Wang T, Watanabe Y, Kalos M. Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen. J Immunol 2004a, 172: 3319-27. (PMID: 14978140)	undefined
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells. Microbiol Immunol 2008, 52: 591-600. (PMID: 19120973)	undefined
Fujie T, Tahara K, Tanaka F, Mori M, Takesako K, Akiyoshi T. A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 1999, 80: 169-72. (PMID: 9935194)	undefined
Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995, 155: 4766-74. (PMID: 7594478)	undefined
Garbe Y, Maletzki C, Linnebacher M. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.ÿPLoS One 2011, 6: e26517. (PMID: 22110587)
Gang Y, Zhang X, He Y, Zheng J, Wu K, Ding J, Fan D. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochem. Cell Biol. 2012, 90: 701-8. (PMID: 22992138)
Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95: 2198-203. (PMID: 10733485)	undefined
Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu W, Lu SY, Chen GS, Sui YF. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther 2004, 3: 891-8. (PMID: 15326372)	undefined
Bredenbeck A, Losch FO, Sharav T, Eichler-Mertens M, Filter M, Givehchi A, Sterry W, Wrede P, Walden P. Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J Immunol 2005, 174: 6716-24. (PMID: 15905511)	undefined
Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, D”hner H, Schmitt M. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 2005, 106: 938-45. (PMID: 15827130)	undefined
Gonzalez FE, Ramirez M, Allerbring EB, Fasching N, Lundqvist A, Poschke I, Achour A, Salazar-Onfray F. 2014. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. Immunobiology 219: 189-97. (PMID: 24192537)
Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996, 10: 693-9. (PMID: 8618449)	undefined
Greiner J, Ono Y, Hofmann S, Schmitt A, Mehring E, Gotz M, Guillaume P, Dohner K, Mytilineos J, Dohner H, Schmitt M. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012, 120: 1282-9. (PMID: 22592607)
Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties. J Immunol 2008, 181: 146-54. (PMID: 18566379)	undefined
Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 2002, 169: 575-80. (PMID: 12077290)	undefined
Gardyan A, Osen W, Zornig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jager D, Eichmuller SB. 2015. Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice. Int J Cancer 136: 2588-97. (PMID: 25387692)
Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998, 160: 328-33. (PMID: 9551988)	undefined
Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999, 163: 4994-5004. (PMID: 10528204)	undefined
Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 1997, 57: 3238-44. (PMID: 9242455)	undefined
Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, Pulford K, Mufti G, Stevenson F, Guinn BA. An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun 2013, 13: 16. (PMID: 23882161)
Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L. Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 2006, 108: 4109-17. (PMID: 16931630)	undefined
Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 2002, 99: 12275-80. (PMID: 12218171)	undefined
Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, Harada K, Mori T, Tsunoda T, Nakatsuru S, Daigo Y, Nomori H, Nakamura Y, Baba H, Nishimura Y. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008, 123: 2616-25. (PMID: 18770861)	undefined
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8: 1731-9. (PMID: 12060610)	undefined
Han JF, Zhao TT, Liu HL, Lin ZH, Wang HM, Ruan ZH, Zou LY, Wu YZ. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother 2006, 55: 1575-83. (PMID: 16534571)	undefined
Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res 1998, 58: 5066-70. (PMID: 9823312)	undefined
Hogan KT, Coppola MA, Gatlin CL, Thompson LW, Shabanowitz J, Hunt DF, Engelhard VH, Ross MM, Slingluff CL Jr. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma. Cancer Res 2004, 64:1157-63. (PMID: 14871852)	undefined
Huang G, Geng J, Wang R, Chen L. Identification of a New Cytotoxic T-Cell Epitope p675 of Human Telomerase Reverse Transcriptase. Cancer Biother Radiopharm 2012, 27: 600-5. (PMID: 22917214)
Huang ZM, Jia ZC, Tang J, Zhang Y, Tian Y, Ni DJ, Wang F, Wu YZ, Ni B. Cross-immunizing potential of tumor MAGE-A epitopes recognized by HLA-A*02:01-restricted cytotoxic T lymphocytes. BMB Rep 2012, 45: 408-13. (PMID: 22831976)
Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 2006, 34: 486-96. (PMID: 16569595)	undefined
Huarte E, Sarobe P, Lasarte JJ, Brem G, Weiss EH, Prieto J, Borras-Cuesta F. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. Int J Cancer 2002, 97: 58-63. (PMID: 11774244)	undefined
Huang YH, Terabe M, Pendleton CD, Stewart Khursigara D, Bera TK, Pastan I, Berzofsky JA. Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE. PLoS One 2013, 8: e64365. (PMID: 23750208)
Ichiki Y, Takenoyama M, Mizukami M, So T, Sugaya M, Yasuda M, Hanagiri T, Sugio K, Yasumoto K. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004, 172: 4844-50. (PMID: 15067062)	undefined
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008, 14: 6487-95. (PMID: 18927288)	undefined
Ida K, Kawaguchi S, Sato Y, Tsukahara T, Nabeta Y, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Kamiguchi K, Wada T, Nagoya S, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Ozaki T, Yoshikawa H, Yamashita T, Sato N. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004, 173: 1436-43. (PMID: 15240740)	undefined
Imai N, Harashima N, Ito M, Miyagi Y, Harada M, Yamada A, Itoh K. Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 2001, 94: 237-42. (PMID: 11668504)	undefined
Ito D, Albers A, Zhao YX, Visus C, Appella E, Whiteside TL, DeLeo AB. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. J Immunol 2006, 177: 6795-803. (PMID: 17082593)	undefined
Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 2000, 88: 633-9. (PMID: 11058882)	undefined
Jäger D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jäger E. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun [serial online] 2005, 5: 11. (PMID: 16335914)
Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006, 103: 14453-8. (PMID: 16984998)	undefined
Jia ZC, Tian Y, Huang ZM, Wang JX, Fu XL, Ni B, Wu YZ. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells. Cancer Biol Ther 2011, 11: 395-400. (PMID: 21124073)
Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 2004, 88: 29-41. (PMID: 15538043)	undefined
Ji J, Judkowski VA, Liu G, Wang H, Bunying A, Li Z, Xu M, Bender J, Pinilla C, Yu JS. Identification of Novel Human Leukocyte Antigen-A*0201-Restricted, Cytotoxic T Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy. Stem Cells Transl. Med. 2014, 3: 356-64. (PMID: 24375541)
Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. Cancer Immunol. Immunother. 2014, 63: 161-74. (PMID: 24233342)
Kawahara M, Hori T, Matsubara Y, Okawa K, Uchiyama T. Identification of HLA class I-restricted tumor-associated antigens in adult T cell leukemia cells by mass spectrometric analysis. Exp Hematol 2006, 34: 1496-504. (PMID: 17046569)	undefined
Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001, 194: 1313-23. (PMID: 11696596)	undefined
Kawamoto M, Tanaka F, Mimori K, Inoue H, Kamohara Y, Mori M. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response. Oncol Rep 2011, 25: 469-76. (PMID: 21165574)
Kawano K, Gomi S, Tanaka K, Tsuda N, Kamura T, Itoh K, Yamada A. Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res 2000, 60: 3550-8. (PMID: 10910068)	undefined
Kawashima H, Obayashi A, Kawamura M, Masaki S, Tamada S, Iguchi T, Uchida J, Kuratsukuri K, Tanaka T, Nakatani T. Galectin 9 and PINCH, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides. B J U 2014, Int 113: 320-32. (PMID: 24895689)
Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate 2007, 67: 1019-28. (PMID: 17455230)	undefined
Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 1999, 81: 459-66. (PMID: 10209962)	undefined
Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJ, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC, Ossendorp F, Melief CJ. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006, 20: 1738-50. (PMID: 16932347)	undefined
Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Schwaiger M, Stevanovic S, Oostendorp RA, Busch DH, Peschel C, Krackhardt AM. 2014. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Leukemia 28: 2355-66 (PMIDÿ: 24736212)
Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998, 47: 90-6. (PMID: 9769117)	undefined
Kierstead LS, Ranieri E, Olson W, Brusic V, Sidney J, Sette A, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer 2001, 85: 1738-45. (PMID: 11742496)	undefined
Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998, 47: 398-403. (PMID: 9510558)	undefined
Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 2014, 9: e93231. (PMID: 24690990)
Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000, 60: 5228-36. (PMID: 11016652)	undefined
Knights AJ, Zaniou A, Rees RC, Pawelec G, Müller L. Prediction of an HLA-DR-binding peptide derived from Wilms? tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol Immunother 2002, 51: 271-81. (PMID: 12070714)	undefined
Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006, 55: 850-60. (PMID: 16220325)	undefined
Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998, 78: 202-8. (PMID: 9754653)	undefined
Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, Findeisen P, von Knebel Doeberitz M. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 2004, 109: 385-92. (PMID: 14961577)	undefined
Koga M, Shichijo S, Yamada A, Ashihara J, Sawamizu H, Kusukawa J, Itoh K. Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue Antigens 2003, 61: 136-45. (PMID: 12694581)	undefined
Kontani K, Teramoto K, Ozaki Y, Fujita T, Tezuka N, Sawai S, Watanabe H, Fujino S, Yokomise H, Ohkubo I. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner. Int J Oncol 2004, 25: 1537-42. (PMID: 15547688)	undefined
Konopitzky R, Konig U, Meyer RG, Sommergruber W, Wolfel T, Schweighoffer T. Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J Immunol 2002, 169: 540-7. (PMID: 12077286)	undefined
Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001, 167: 787-96. (PMID: 11441084)	undefined
Kumai T, Matsuda Y, Ohkuri T, Oikawa K, Ishibashi K, Aoki N, Kimura S, Harabuchi Y, Celis E, Kobayashi H. 2015. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology 4: e976077 (PMIDÿ: 25949874)
Lee JH, Park MS, Hwang JE, Cho SH, Bae WK, Shim HJ, Kim DE, Chung IJ. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Cell. Mol. Immunol. 2013, 10: 275-82. (PMID: 23524651)
Li G, Hundemer M, Wolfrum S, Ho AD, Goldschmidt H, Witzens-Harig M. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). Ann Hematol 2006, 85: 583-90. (PMID: 16718496)	undefined
Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998, 47: 32-8. (PMID: 9755876)	undefined
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 2008, 52: 551-8. (PMID: 19090835)	undefined
Li B, Wang Y, Chen J, Wu H, Chen W. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587. Clin Exp Immunol 2005, 140: 310-9. (PMID: 15807856)	undefined
Krämer BF, Schoor O, Krüger T, Reichle C, Müller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee H-G, Stevanovic S. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther 2005, 4: 943-8. (PMID: 16082191)	undefined
Liu F, Zhang H, Shen D, Wang S, Ye Y, Chen H, Pang X, Song Q, He P. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1. J. Gastroenterol. 2014, 49: 419-26. (PMID: 23604623)
Liu W, Zhai M, Wu Z, Qi Y, Wu Y, Dai C, Sun M, Li L, Gao Y. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer. Amino Acids 2012, 42: 2257-65. (PMID: 21710262)
Liu Y, Daley S, Evdokimova VN, Zdobinski DD, Potter DM, Butterfield LH. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol 2006, 177: 712-21. (PMID: 16785570)	undefined
Lotz C, Mutallib SA, Oehlrich N, Liewer U, Ferreira EA, Moos M, Hundemer M, Schneider S, Strand S, Huber C, Goldschmidt H, Theobald M. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol 2005, 175: 1301-9. (PMID: 16002735)	undefined
Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002, 62: 5807-12. (PMID: 12384542)	undefined
Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D?Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. Clin Cancer Res 2008, 14: 7292-303. (PMID: 18974390)	undefined
Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005, 65: 6435-42. (PMID: 16024648)	undefined
Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes. Cancer Immunol Immunother 2007, 56: 1565-75. (PMID: 17318652)	undefined
Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. 2015. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A 112: E166-75. (PMID: 25548167)
Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006, 12: 1365-72. (PMID: 16489095)	undefined
Maia S, Haining WN, Ans‚n S, Xia Z, Armstrong SA, Seth NP, Ghia P, den Boer ML, Pieters R, Sallan SE, Nadler LM, Cardoso AA. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res 2005, 65: 10050-8. (PMID: 16267031)	undefined
Mahlendorf DE, Staege MS. Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol. Ther. 2013, 14: 254-61. (PMID: 23291981)
Maeda A, Ohguro H, Nabeta Y, Hirohashi Y, Sahara H, Maeda T, Wada Y, Sato T, Yun C, Nishimura Y, Torigoe T, Kuroki Y, Sato N. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol 2001, 31: 563-72. (PMID: 11180121)	undefined
Matsueda S, Wang M, Weng J, Li Y, Yin B, Zou J, Li Q, Zhao W, Peng W, Legras X, Loo C, Wang RF, Wang HY. Identification of prostate-specific g-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One 2012, 7: e45756. (PMID: 23029225)
Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, MaillŠre B, Kirkwood JM, Zarour HM. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by Th1-type tumor-reactive CD4+ T cells. Cancer Res 2003, 63: 6506-6515. (PMID: 14559844)	undefined
May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms? tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007, 13: 4547-55. (PMID: 17671141)	undefined
Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, Straten PT, Mueller L, Rees RC, McArdle SE. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother 2007, 56: 1885-95. (PMID: 17487488)	undefined
Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner C-M. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 2006, 34: 44-53. (PMID: 16413390)	undefined
Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Sondergaard I, Andersen MH, Thor Straten P. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother 2005, 54: 219-28. (PMID: 15580499)	undefined
Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 2007, 56: 689-98. (PMID: 16937115)	undefined
Mitchell MS, Kan-Mitchell J, Minev B, Edman C, Deans RJ. A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes. Cancer Res 2000, 60: 6448-56. (PMID: 11103812)	undefined
Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma. Int Immunopharmacol 2014, 20: 59-65. (PMID: 24583149)
Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine 2010, 28: 5338-46. (PMID: 20665979)
Mizote Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. 2014. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients. Vaccine 32: 957-64. (PMID: 24397899)
Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. Int J Cancer 2006, 118: 1194-204. (PMID: 16152611)	undefined
Morioka N, Kikumoto Y, Hoon DS, Morton DL, Irie RF. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 1995, 32: 573-81. (PMID: 7541891)	undefined
Morel S, L‚vy F, Burlet-Schiltz O, Brasseur F, Probst-Kepper M, Peitrequin AL, Monsarrat B, Van Velthoven R, Cerottini JC, Boon T, Gairin JE, Van den Eynde BJ. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000, 12: 107-17. (PMID: 10661410)	undefined
Müller L, Knights A, Pawelec G. Synthetic peptides derived from the Wilms? tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J 2003, 4: 57-66. (PMID: 12692522)	undefined
Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res 2004, 64: 5481-8. (PMID: 15289358)	undefined
Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One 2012, 7: e34568. (PMID: 22539948)
Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer 2005, 115: 333-6. (PMID: 15688394)	undefined
Matsueda S, Takedatsu H, Sasada T, Azuma K, Ishihara Y, Komohara Y, Noguchi M, Shichijo S, Itoh K, Harada M. New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles. J Immunother 2007, 30: 274-81. (PMID: 17414318)	undefined
Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers. Eur. J. Cancer 2013, 49: 2587-95. (PMID: 23561850)
Myers CE, Hanavan P, Antwi K, Mahadevan D, Nadeem AJ, Cooke L, Scheck AC, Laughrey Z, Lake DF. CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells. Cancer Immunol Immunother 2011, 60: 1319-32. (PMID: 21626031)
Nagata Y, Hanagiri T, Takenoyama M, Fukuyama T, Mizukami M, So T, Ichiki Y, Sugaya M, Sugio K, Yasumoto K. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 2005, 11: 5265-72. (PMID: 16033845)	undefined
Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002, 32: 826-36. (PMID: 11870627)	undefined
Nakao M, Shichijo S, Imaizumi T, Inoue Y, Matsunaga K, Yamada A, Kikuchi M, Tsuda N, Ohta K, Takamori S, Yamana H, Fujita H, Itoh K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol 2000, 164: 2565-74. (PMID: 10679095)	undefined
Neumann A, Horzer H, Hillen N, Klingel K, Schmid-Horch B, Buhring HJ, Rammensee HG, Aebert H, Stevanovic S. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol. Immunother. 2013, 62: 1485-97. (PMID: 23817722)
Nonaka Y, Tsuda N, Shichijo S, Ito M, Maeda Y, Harada M, Kamura T, Shigemori M, Itoh K. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 2002, 60: 319-27. (PMID: 12472661)	undefined
Nunes CT, Miners KL, Dolton G, Pepper C, Fegan C, Mason MD, Man S. A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res 2011, 71: 5435-44. (PMID: 21697278)
Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A 2010, 107: 15187-92. (PMID: 20696919)
Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004, 64: 2610-8. (PMID: 15059918)	undefined
Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000, 109: 616-21. (PMID: 10886212)	undefined
Ohkouchi S, Kawamoto N, Koga M, Sakanashi F, Shichijo S, Saijo Y, Nukiwa T, Itoh K, Yamada A. Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur J Immunol 2003, 33: 2964-73. (PMID: 14579264)	undefined
Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, Fujita S. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999, 93: 925-35. (PMID: 9920842)	undefined
Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T. 2014. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunol Lett 161: 20-30. (PMID: 24794408)
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 2010, 59: 943-53. (PMID: 20140431)
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood 2011, 117: 3353-62. (PMID: 21278353)
Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms? tumor gene (WT1 ) product. Immunogenetics 2000, 51: 99-107. (PMID: 10663572)	undefined
Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003, 15: 751-63. (PMID: 12750359)	undefined
Ras E, van der Burg SH, Zegveld ST, Brandt RM, Kuppen PJ, Offringa R, Warnarr SO, van de Velde CJ, Melief CJ. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 1997, 53: 81-9. (PMID: 9127151)	undefined
Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 2006, 118: 50-7. (PMID: 16630022)	undefined
Osawa R, Tsunoda T, Yoshimura S, Watanabe T, Miyazawa M, Tani M, Takeda K, Nakagawa H, Nakamura Y, Yamaue H. Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol 2012, 2012: 848042. (PMID: 22778556)
Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995, 154: 5944-50. (PMID: 7751637)	undefined
Paschen A, Jing W, Drexler I, Klemm M, Song M, Müller-Berghaus J, Nguyen XD, Osen W, Stevanovic S, Sutter G, Schadendorf D. Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2. Int J Cancer 2005, 116: 944-8. (PMID: 15856458)	undefined
Rodeberg DA, Nuss RA, Elsawa SF, Erskine CL, Celis E. Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. Int J Cancer 2006, 119: 126-32. (PMID: 16450380)	undefined
Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 2005, 65: 10068-78. (PMID: 16267033)	undefined
Rojas JM, McArdle SEB, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC. Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. Cancer Immunol Immunother 2005, 54: 243-53. (PMID: 15449037)	undefined
Okumura H, Noguchi Y, Uenaka A, Aji T, Ono T, Nakagawa K, Aoe M, Shimizu N, Nakayama E. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Microbiol Immunol 2005, 49: 1009-16. (PMID: 16301813)	undefined
Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996, 88: 2118-24. (PMID: 8822931)	undefined
Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AML, Lemonnier FA, Kosmatopoulos K, Gambacorti-Passerini C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002, 99: 2100-6. (PMID: 11877285)	undefined
Saeterdal I, Bjorheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 2001, 98: 13255-60. (PMID: 11687624)	undefined
Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, Ito N, Hasegawa T, Tsukamoto T, Sato N. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 2008, 14: 6916-23. (PMID: 18980986)	undefined
Salazar-Onfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, Celis E, Sette A, Southwood S, Appella E, Kiessling R. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997, 57: 4348-55. (PMID: 9331097)	undefined
Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002, 98: 409-14. (PMID: 11920592)	undefined
Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res 2003, 9: 3260-71. (PMID: 12960111)	undefined
Sato Y, Nabeta Y, Tsukahara T, Hirohashi Y, Syunsui R, Maeda A, Sahara H, Ikeda H, Torigoe T, Ichimiya S, Wada T, Yamashita T, Hiraga H, Kawai A, Ishii T, Araki N, Myoui A, Matsumoto S, Umeda T, Ishii S, Kawaguchi S, Sato N. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol 2002, 169: 1611-8. (PMID: 12133991)	undefined
Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol Immunother 2005 , 54: 703-12. (PMID: 15726360)	undefined
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmuller SB, Okun J, Stevanovic S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512: 324-7. (PMID: 25043048)
Sharkey MS, Liz‚e G, Gonzales MI, Patel S, Topalian SL. CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004, 64: 1595-9. (PMID: 14996715)	undefined
Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 2003, 100: 3398-403. (PMID: 12626761)	undefined
Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Ritter G, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun [serial online] 2003, 3: 19. (PMID: 14680360)
Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998, 187: 277-88. (PMID: 9449708)	undefined
Shen H, Shao HW, Chen XH, Wu FL, Wang H, Huang ZL, Shen J, Wang T, Zhang WF, Huang SL. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen. Cancer Immunol. Immunother. 2013, 62: 393-403. (PMID: 22926105)
Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Clin Cancer Res 2004, 10: 5828-36. (PMID: 15355913)	undefined
Smith HA, McNeel DG. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. J Immunother 2011, 34: 569-80. (PMID: 21904219)
So T, Takenoyama M, Mizukami M, Ichiki Y, Sugaya M, Hanagiri T, Sugio K, Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 2005, 65: 5945-52. (PMID: 15994973)	undefined
Smyth LJ, Elkord E, Taher TE, Jiang HR, Burt DJ, Clayton A, van Veelen PA, de Ru A, Ossendorp F, Melief CJ, Drijfhout JW, Dermime S, Hawkins RE, Stern PL. Cd8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006, 119: 1638-147. (PMID: 16646078)	undefined
Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006, 66: 3287-93. (PMID: 16540682)	undefined
Sasada T, Takedatsu H, Azuma K, Koga M, Maeda Y, Shichijo S, Shoumura H, Hirai T, Takabayashi A, Itoh K. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 2004, 64: 2882-8. (PMID: 15087407)	undefined
Santomasso BD, Roberts WK, Thomas A, Williams T, Blachere NE, Dudley ME, Houghton AN, Posner JB, Darnell RB. A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A 2007, 104: 19073-8. (PMID: 18045792)	undefined
Sommerfeldt N, Beckhove P, Ge Y, Schütz F, Choi C, Bucur M, Domschke C, Sohn C, Schneeweis A, Rom J, Pollmann D, Leucht D, Vlodavsky I, Schirrmacher V. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 2006, 66: 7716-23. (PMID: 16885374)	undefined
Sorensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, Andersen MH, thor Straten P. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res 2009, 15: 1543-9. (PMID: 19223507)	undefined
Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res. 2011, 71: 2038-44. (PMID: 21406395)
Sun Y, Song M, Stevanovic S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer 2000, 87: 399-404. (PMID: 10897046)	undefined
Sun Y, Stevanovic S, Song M, Schwantes A, Kirkpatrick CJ, Schadendorf D, Cichutek K. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood 2006, 107: 1476-83. (PMID: 16234362)	undefined
Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, Chiba S, Juji T, Hirai H. Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes. Br J Haematol 2000, 109: 435-7. (PMID: 10848838)	undefined
Sun Y, Song M, Jager E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR. Clin Cancer Res 2008, 14: 4306-15. (PMID: 18594014)	undefined
Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011, 60: 809-18. (PMID: 21365467)	undefined
Tamura M, Nishizaka S, Maeda Y, Ito M, Harashima N, Harada M, Shichijo S, Itoh K. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes. Jpn J Cancer Res 2001, 92: 762-7. (PMID: 11473727)	undefined
Suzuki K, Sahara H, Okada Y, Yasoshima T, Hirohashi Y, Nabeta Y, Hirai I, Torigoe T, Takahashi S, Matsuura A, Takahashi N, Sasaki A, Suzuki M, Hamuro J, Ikeda H, Wada Y, Hirata K, Kikuchi K, Sato N. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 1999, 163: 2783-91. (PMID: 10453022)	undefined
Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63: 4481-9. (PMID: 12907621)	undefined
ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC. Recognition of peptides corresponding to the joining region of p210 BCR-ABL protein by human T cells. Leukemia 1995, 9: 1344-8. (PMID: 7643623)	undefined
Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003, 9: 947-54. (PMID: 12631591)	undefined
Touloukian CE, Leitner WW, Robbins PF, Rosenberg SA, Restifo NP. Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. Cancer Res 2001, 61: 8100-4. (PMID: 11719435)	undefined
ten Bosch GJ, Kessler JH, Joosten AM, Bres-Vloemans AA, Geluk A, Godthelp BC, van Bergen J, Melief CJ, Leeksma OC. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood 1999, 94: 1038-45. (PMID: 10419896)	undefined
Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res 2001, 61: 4761-5. (PMID: 11406549)	undefined
Tsukahara T, Kawaguchi S, Torigoe T, Takahashi A, Murase M, Kano M, Wada T, Kaya M, Nagoya S, Yamashita T, Sato N. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med 2009, 7: 44. (PMID: 19523231)	undefined
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002, 51: 614-20. (PMID: 12439606)	undefined
Tu SH, Huang HI, Lin SI, Liu HY, Sher YP, Chiang SK, Chong P, Roffler S, Tseng GC, Chen HW, Liu SJ. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo. J Immunother 2012, 35: 235-44. (PMID: 22421941)
Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997, 57: 4465-8. (PMID: 9377553)	undefined
Visseren MJ, van der Burg SH, van der Voort EI, Brandt RM, Schrier PI, van der Bruggen P, Boon T, Melief CJ, Kast WM. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997, 73: 125-30. (PMID: 9334819)	undefined
Visus C, Ito D, Dhir R, Szczepanski MJ, Chang YJ, Latimer JJ, Grant SG, DeLeo AB. Identification of Hydroxysteroid (17beta) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas. Cancer Immunol Immunother 2011, 60: 919-29. (PMID: 21409596)
van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res 2006, 66: 1818-23. (PMID: 16452243)	undefined
Viehl CT, Frey DM, Phommaly C, Chen T, Fleming TP, Gillanders WE, Eberlein TJ, Goedegebuure PS. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies. Breast Cancer Res Treat 2008, 109: 305-14. (PMID: 17653857)	undefined
Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches. Cancer Res 2007, 67: 5300-7. (PMID: 17545610)	undefined
Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002, 62: 5818-27. (PMID: 12384544)	undefined
Voo KS, Zeng G, Mu JB, Zhou J, Su XZ, Wang RF. CD4+ T-cell response to mitochondrial cytochrome B in human melanoma. Cancer Res 2006, 66: 5919-26. (PMID: 16740732)	undefined
Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 2001, 7: 3343-8. (PMID: 11705846)	undefined
Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immun [serial online] 2003, 3: 18. (PMID: 14677925)
Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J Immunol 2008, 181: 431-9. (PMID: 18566409)	undefined
Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 2012, 120: 1613-23. (PMID: 22645177)
Wagner WM, Ouyang Q, Pawelec G. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes. Cancer Immunol Immunother 2003, 52: 89-96. (PMID: 12594572)	undefined
Würtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002, 99: 568-72. (PMID: 11992547)	undefined
Wu ZY, Gao YF, Wu YH, Liu W, Sun M, Zhai MX, Qi YM, Ye Y. Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma. Scand J Immunol 2011, 74: 561-7. (PMID: 21815906)
Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001, 84: 1052-7. (PMID: 11308253)	undefined
Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 2006, 76: 23-30. (PMID: 16155724)	undefined
van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31: e439-42. (PMID: 24043743)
Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59: 4056-63. (PMID: 10463607)	undefined
Yamaguchi H, Tanaka F, Ohta M, Inoue H, Mori M. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res 2004, 10: 890-6. (PMID: 14871964)	undefined
Yatsuda J, Irie A, Harada K, Michibata Y, Tsukamoto H, Senju S, Tomita Y, Yuno A, Hirayama M, Abu Sayem M, Takeda N, Shibuya I, Sogo S, Fujiki F, Sugiyama H, Eto M, Nishimura Y. Establishment of HLA-DR4 transgenic mice for the identification of CD4+ T cell epitopes of tumor-associated antigens. PLoS One 2013, 8: e84908. (PMID: 24386437)
Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005, 11: 6342-51. (PMID: 16144939)	undefined
Zarling AL, Polefrone JM, Evans AM, Mikesh LM, Shabanowitz J, Lewis ST, Engelhard VH, Hunt DF. 2006. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc Natl Acad Sci U S A 103: 14889-94 (PMID: 17001009)
Yuan B, Zhao L, Xian R, Zhao G. Identification of novel HLA-A(*)0201-restricted CTL epitopes from Pokemon. Cell Immunol 2012, 274: 54-60. (PMID: 22405859)
Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003, 170: 5391-7. (PMID: 12759413)	undefined
Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin. Cancer Res. 2013, 19: 247-57. (PMID: 23147993)
Zhu B, Chen Z, Cheng X, Lin Z, Guo J, Jia Z, Zou L, Wang Z, Hu Y, Wang D, Wu Y. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin Cancer Res 2003, 9: 1850-7. (PMID: 12738743)	undefined
Zhou J, Yuen NK, Zhan Q, Velazquez EF, Murphy GF, Giobbie-Hurder A, Hodi FS. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP, livin) in patients with malignant melanoma. Cancer Immunol Immunother 2012, 61: 655-65. (PMID: 22033581)
Xu W, Li HZ, Liu JJ, Guo Z, Zhang BF, Chen FF, Pei DS, Zheng JN. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from proliferating cell nuclear antigen. Tumour Biol 2011, 32: 63-9. (PMID: 20711822)
Yang Z, Zhao T, Liu Y, Gong Z, Cheng S, Yang Q. Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin. J. Neurooncol. 2013, 114: 51-8. (PMID: 23754640)
Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001, 61: 6459-66. (PMID: 11522641)	undefined
Yamada A, Kawano K, Koga M, Takamori S, Nakagawa M, Itoh K. Gene and peptide analyses of newly defined lung cancer antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T lymphocytes. Cancer Res 2003, 63: 2829-35. (PMID: 12782588)	undefined
Yan Y, Chen Y, Yang F, Chen IH, Xiong Z, Wang J, Lachman LB, Wang H, Yang XF. HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells. Int J Immunopathol Pharmacol 2007, 20: 75-89. (PMID: 17346430)	undefined
Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, Miyakuni T, Nakao S, Kishi K, Kubonishi I, Dan K, Fujita S. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998, 92: 3355-61. (PMID: 9787173)	undefined
Matsueda S, Shichijo S, Nagata S, Seki C, Yamada A, Noguchi M, Itoh K. Identification of novel Lck-derived T helper epitope long peptides applicable for HLA-A2(+) cancer patients as cancer vaccine. Cancer Sci 2015, 106: 1493-8. (PMID: 26331453)
Wang L, Xu Y, Luo C, Sun J, Zhang J, Lee MW, Bai A, Chen G, Frenz CM, Li Z, Huang W. MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A(∗)0201 alleles. Cell Immunol 2015, 297: 10-8. (PMID: 26058806)
Capello M, Caorsi C, Bogantes Hernandez PJ, Dametto E, Bertinetto FE, Magistroni P, Rendine S, Amoroso A, Novelli F. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. Immunol Lett 2015, 167: 11-6. (PMID: 26096821)
Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int J Cancer 2015, 137:116-26. (PMID: 25449106)
Tang B, Zhou W, Du J, He Y, Li Y. Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep 2015, 12: 1741-52. (PMID: 25936538)
Horiuchi Y, Takagi A, Uchida T, Akatsuka T. Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo. Oncol Rep 2015, 34: 2827-36. (PMID: 26398429)
Brentville VA, Metheringham RL, Gunn B, Symonds P, Daniels I, Gijon M, Cook K, Xue W, Durrant LG. Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity. Cancer Res 2016, 76: 548-60. (PMID: 26719533)
K Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wölfel T, Damm-Welk C, Woessmann W. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma. Clin Exp Immunol 2016, 186: 96-105. (PMID: 27414060)
Müller I, Altherr D, Eyrich M, Flesch B, Friedmann KS, Ketter R, Oertel J, Schwarz EC, Technau A, Urbschat S, Eichler H. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients. Cytotherapy 2016, 18(9) :1146-61. (PMID: 27424145)
Dhiman G, Lohia N, Jain S, Baranwal M. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer. Microbiol Immunol 2016, 60: 646-52. (PMID: 27554419)
Peper JK, Bösmüller HC, Schuster H, Gückel B, Hörzer H, Roehle K, Schäfer R, Wagner P, Rammensee HG, Stevanović S, Fend F, Staebler A. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology 2015, 5: e1065369. (PMID: 26096821)
Kim YH, Tran TA, Lee HJ, Jung SI, Lee JJ, Jang WY, Moon KS, Kim IY, Jung S, Jung TY. Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99. Oncotarget 2016, 7: 50535-47. (PMID: 27409668)
Lu C, Meng S, Jin Y, Zhang W, Li Z, Wang F, Wang-Johanning F, Wei Y, Liu H, Tu H, Su D, He A, Cao X, Zhou F. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol 2017, 178: 413-426. (PMID: 28508448)
Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. Int Immunopharmacol 2017, 44: 197-202. (PMID: 28110220)
Xie X, Zhou W, Hu Y, Chen Y, Zhang H, Li Y. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. Cell Death Dis 2018, 9: 379. (PMID: PMC5841361)
Zhang J, Sang M, Gu L, Liu F, Li W, Yin D, Wu Y, Liu S, Huang W, Shan B. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide. J Immunother 2017, 40: 211-220. (PMID: 28486273)
Gnjatic S, Atanackovic D, Matsuo M, Jäger E, Lee SY, Valmori D, Chen YT, Ritter G, Knuth A, Old LJ. Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs. J Immunol 2003, 170: 1191-6. (PMID: 12538675)
Jackson H, Dimopoulos N, Mifsud NA, Tai TY, Chen Q, Svobodova S, Browning J, Luescher I, Stockert L, Old LJ, Davis ID, Cebon J, Chen W. Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses to Tumor Antigen NY-ESO-1. J Immunol 2006, 176: 5908-17. (PMID: 6670298)
Bae J, Hideshima T, Zhang GL, Zhou J, Keskin DB, Munshi NC, Anderson KC. Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia. 2018 Mar, 32(3):752-764. (PMID: 29089645)
Majumder S, Shah R, Elias J, Mistry Y, Coral K, Shah P, Maurya AK, Mittal B, D'Silva JK, Murugan S, Mahadevan L, Sathian R, Ramprasad VL, Chakraborty P, Gupta R, Chaudhuri A, Khanna-Gupta A. A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. PLoS One. 2018 Sep 26, 13(9):e0203845. (PMID: 30256815)
Matko S, Manderla J, Bonsack M, Schmitz M, Bornhauser M, Tonn T, Odendahl M. PRAME peptide-specific CD8+ T cells represent the predominant response against leukemia-associated antigens in healthy individuals. Eur J Immunol. 2018 Aug, 48(8):1400-1411. (PMID: 29738081)
Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun. 2019 Jan 25, 10(1):449.
Iiizumi S, Ohtake J, Murakami N, Kouro T, Kawahara M, Isoda F, Hamana H, Kishi H, Nakamura N, Sasada T. Identification of novel HLA class II-restricted neoantigens derived from driver mutations. Cancers (Basel). 2019 Feb 24, 11(2). pii: E266. (PMID: 30813491)
Watanabe K, Tsukahara T, Toji S, Saitoh S, Hirohashi Y, Nakatsugawa M, Kubo T, Kanaseki T, Kameshima H, Terui T, Sato N, Torigoe T. Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells. Cancer Sci. 2019 Jan, 110(1):40-51. (PMID: 30375705)
Tubb VM, Schrikkema DS, Croft NP, Purcell AW, Linnemann C, Freriks MR, Chen F, Long HM, Lee SP, Bendle GM. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies. J. Immunother. Cancer. 2018, 6(1): 70. (PMID: 30001747)
Zhang M, Fritsche J, Roszik J, Williams LJ, Peng X, Chiu Y, Tsou CC, Hoffgaard F, Goldfinger V, Schoor O, Talukder A, Forget MA, Haymaker C, Bernatchez C, Han L, Tsang YH, Kong K, Xu X, Scott KL, Singh-Jasuja H, Lizee G, Liang H, Weinschenk T, Mills GB, Hwu P. RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat. Commun. 2018, 9(1): 3919. (PMID: 30254248)
Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y. Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discov. 2018, 8(11): 1366-1375. (PMID: 30209080)
Ferulli F, Tanzi M, Turin I, Montini E, Rosti V, Acquafredda G, Lisini D, Compagno F, Boghen S, Licari A, Marseglia G, Zecca M, Montagna D. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. Cytotherapy 2019, 21: 958-972. (PMID: 3127969)
Safavi A, Kefayat A, Abiri A, Mahdevar E, Behnia AH, Ghahremani F. In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. Mol Immunol 2019, 112: 93-102. (PMID: 31079006)
Shi W, Qiu Q, Tong Z ,Guo W, Zou F, Feng Z, Wang Y, Huang W, Qian H. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells. Eur J Med Chem 2020, 189: 112051. (PMID: 31968280)
Besneux M, Greenshields-Watson A, Scurr MJ, MacLachlan BJ, Christian A, Davies MM, Hargest R, Phillips S, Godkin A, Gallimore A. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunol Immunother 2019, 68: 247-256. (PMID: 30406375)
Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS, The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 2019, 133: 550-565. (PMID: 30530751)
Xiang SD, Wilson KL, Goubier A, Heyerick A, Plebanski M. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses. Front Immunol 2018, 9: 2968. (PMID: 30631324)
Khalaf WS, Garg M, Mohamed YS, Stover CM, Browning MJ. In vitro Generation of Cytotoxic T Cells With Potential for Adoptive Tumor Immunotherapy of Multiple Myeloma. Front Immunol 2019,10: 1792. (PMID: 31428094)
Milcent B, Josseaume N, Riller Q, Giglioli I, Rabia E, Deligne C, Latouche JB, Hamieh M, Couture A, Toutirais O, Lone YC, Jeger-Madiot R, Graff-Dubois S, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S. Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunol Immunother 2019, 68:1561-1572. (PMID: 31494742)
Meng Q, Valentini D, Rao M, Moro CF, Paraschoudi G, Jäger E, Dodoo E, Rangelova E, Del Chiaro M, Maeurer M. Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. Br J Cancer 2019, 120: 97-108. (PMID: 30377343)
Bharat, A., Benshoff, N., Fleming, T.P. et al. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers. Breast Cancer Res Treat 2008, 110:453-463. (PMID: 17874294)
Bae J, Samur M, Richardson P, Munshi NC, Anderson KC. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia 2019, 33: 2208-2226. (PMID: 30872779)
Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T. A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Sci. 2021, 112(7):2705-2713. (PMID: 34009705)
Stanojevic M, Hont AB, Geiger A, O'Brien S, Ulrey R, Grant M, Datar A, Lee PH, Lang H, Cruz CRY, Hanley PJ, Barrett AJ, Keller MD, Bollard CM. Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies. Cytotherapy. 2021, 23(8):694-703. (PMID: 33832817)
Sugata K, Matsunaga Y, Yamashita Y, Nakatsugawa M, Guo T, Halabelian L, Ohashi Y, Saso K, Rahman MA, Anczurowski M, Wang CH, Murata K, Saijo H, Kagoya Y, Ly D, Burt BD, Butler MO, Mak TW, Hirano N. Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nat Biotechnol. 2021, . (PMID: 33649568)
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. Oncoimmunology. 2020, 10(1):1856545. (PMID: 33457076)
Bai J, Wang J, Yang Y, Wang F, He A, Zhang W. Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia. J Immunother. 2021, 44(4):141-150. (PMID: 33596023
Kan S, Bito T, Shimabuku M, Taguchi J, Ohkusa T, Shimodaira S, Sugiyama H, Koido S. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA A2 restricted WT1 reactive CD8+ T cells. Int J Oncol. 2020, 57(4):1047-1056. (PMID: 32945369).
Dimou A, Grewe P, Sidney J, Sette A, Norman PJ, Doebele RC. HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival. J Thorac Oncol. 2021, 16(1):104-112. (PMID: 32927123)
Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, Walz JS. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. Blood Cancer J. 2020, 10(2):24 (PMID: 32111817)
Viborg N, Ramskov S, Andersen RS, Sturm T, Fugmann T, Bentzen AK, Rafa VM, Straten PT, Svane IM, Met Ö, Hadrup SR. T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. Oncoimmunology. 2019, 8(12):e1663107. (PMID: 31741759)
Nyambura LW, Muñoz AA, le Coutre P, Walden P. HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells. Sci Rep. 2019, 9(1):14029 (PMID: 31575892)
Soh JE, Abu N, Sagap I, Mazlan L, Yahaya A, Mustangin M, Khoo TS, Saidin S, Ishak M, Ab Mutalib NS, Jamal R. Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer. Immunotherapy. 2019, 11(14):1205-1219 (PMID: 31478431)
Thomas R, Shaath H, Naik A, Toor SM, Elkord E, Decock J. Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy. Cancer Immunol Immunother 2020, 69(3):449-463. (PMID: 31932876)
Engelhard VH, Obeng RC, Cummings KL, Petroni GR, Ambakhutwala AL, Chianese-Bullock KA, Smith KT, Lulu A, Varhegyi N, Smolkin ME, Myers P, Mahoney KE, Shabanowitz J, Buettner N, Hall EH, Haden K, Cobbold M, Hunt DF, Weiss G, Gaughan E, Slingluff CL Jr. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. J Immunother Cancer. 2020 e000262 (PMID: 32385144)
Brentville VA, Metheringham RL, Daniels I, Atabani S, Symonds P, Cook KW, Vankemmelbeke M, Choudhury R, Vaghela P, Gijon M, Meiners G, Krebber WJ, Melief CJM, Durrant LG. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. J Immunother Cancer. 2020 e000560. (PMID: 32561639)

Selected reference: